Search criteria | ||||
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | ||||
Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group | ||||
"1 Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel 2 Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany 3 German Centre for Diabetes Research (DZD), München-Neuherberg, Germany 4 Department of Health Service Administration, China Medical University, Taichung, Taiwan 5 Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan 6 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 7 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 8 Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan 9 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 10 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 11 Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK 12 Institute of Applied Health Research, University of Birmingham, Birmingham, UK 13 Midlands Health Data Research UK, Birmingham, UK 14 DEMAND Hub, University of Birmingham, Birmingham, UK 15 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden 16 Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland 17 IQVIA Solutions Denmark A/S, Copenhagen, Denmark 18 IQVIA, Espoo, Finland 19 IQVIA, Tartu, Estonia 20 Boehringer Ingelheim International GmbH, Ingelheim, Germany 21 Boehringer Ingelheim International GmbH, US 22 Lilly Deutschland GmbH, Bad Homburg, Germany 23 Steno Diabetes Center Copenhagen, Herlev, Denmark 24 Department of Public Health, University of Copenhagen, Copenhagen, Denmark 25 Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway 26 Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway 27 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA 28 Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" | ||||
"Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636 Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October" |
||||
, Article | ||||
, Denmark, Finland, Germany, Norway, Spain, Sweden, UK | ||||
Abstract: https://doi.org/10.1016/j.diabet.2022.101418 (https://www.sciencedirect.com/science/article/pii/S1262363622000994) | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study | 2023 | English | , Clinical setting: hospital, Clinical setting: Primary care | |
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis | ||||
Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore, Aida Aydemir, Irene Bezemer & Meritxell Sabidó | ||||
"a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia; b The Alfred Hospital, Melbourne, VIC, Australia; c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland; e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany; f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland; g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland; h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; i Department of Clinical Medicine, University of Bergen, Bergen, Norway; j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; l Bordeaux PharmacoEpi (BPE), Universit�e de Bordeaux, Bordeaux, France; m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA; n Global Epidemiology, IQVIA, Amsterdam, The Netherlands; o Merck Healthcare KGaA, Darmstadt, Germany" | ||||
, Article | ||||
, Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey | ||||
Abstract: https://www.tandfonline.com/doi/full/10.1080/03007995.2023.2256220 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders | 2023 | English | , clinical setting: Secondary care, Epidemiological study, Population Based Study | |
Burden of Hospitalizations and Outpatient Visits Associated With Moderate and Severe Acute Graft-Versus-Host Disease in Finland and Sweden: A Real-World Data Analysis | ||||
Lorenzo Sabatelli, PhD,1 Mikko Keränen, MD, PhD,2 Elisabet Viayna, PhD,3 Montserrat Roset, BSc Stats,3 Nuria Lara, MD, MSc,3 Daniel Thunström, MSc Pharm,1 Minja Pfeiffer, PhD,1 Malin Nicklasson, MSc Pharm,4 Maija Itälä-Remes, MD, PhD5 | ||||
"1Incyte Biosciences International Sàrl, Morges, Switzerland; 2Helsinki University Hospital, Helsinki, Finland; 3IQVIA Real World Solutions, Barcelona, Spain; 4Department of Hematology and Coagulation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 5Turku University Hospital, Turku, Finland " | ||||
Supportive Care in Cancer |
||||
, Article | ||||
, Finland, Spain, Sweden, Switzerland | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Transplant | 2022 | English | , Clinical setting: hospital, Observational study, Population Based Study | |
The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets | ||||
Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group | ||||
1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia. 2The Alfred Hospital, Melbourne, Australia. 3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France. 4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA). 5Global Database Studies, IQVIA, Tartu, Estonia. 6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands. 7IQVIA (former EPID Research), Espoo, Finland. 8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany. | ||||
Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977 |
||||
, Article | ||||
, Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/35357268/ | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Neurological disorders | 2022 | English | , clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis | |
Treatment Patterns, Socioeconomic Status and Clinical Burden in Mild COPD: A Swedish Real-World, Retrospective Cohort Study, the ARCTIC Study | ||||
Kjell Larsson,1 Karin Lisspers,2 Björn Ställberg,2 Gunnar Johansson,2 Florian S Gutzwiller,3 Karen Mezzi,3 Bine Kjoeller Bjerregaard,4 Leif Jorgensen,4 Hyewon Koo,5 Christer Janson6 | ||||
1Integrative Toxicology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 2Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 3Novartis Pharma AG, Basel, Switzerland; 4IQVIA Solutions, Copenhagen, Denmark; 5IQVIA Solutions, Solna, Sweden; 6Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden | ||||
International Journal of Chronic Obstructive Pulmonary Disease 2022:17 1409?1421 https://doi.org/10.2147/COPD.S364932 PMID 35761954 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.dovepress.com/articles.php?article_id=76070 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2022 | English | , Clinical setting: Primary care, Epidemiological study, Population Based Study, Real World Data, Retrospective cohort analysis | |
Validation of safety outcomes in routinely collected data: lessons learned from a multinational post-approval safety study | ||||
Arena PJ, Huang K, Löfling L, Bahmanyar S, Mo J, Schachterle SE, Nunes AP, Smits E, Juuti R, Hoti F, Korhonen P, Adelborg K, Sundbøll J, Rasmussen TR, Løkke A, Ehrenstein V. | ||||
"Pfizer Inc., New York, New York, United States of America. Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California, United States of America. EPID Research (an IQVIA company), Espoo, Finland." | ||||
Pharmacoepidemiol Drug Saf. 2022 Dec 10. doi: 10.1002/pds.5582 |
||||
, Article | ||||
, Denmark, Finland, Netherlands , Sweden, USA | ||||
Abstract: https://onlinelibrary.wiley.com/doi/10.1002/pds.5582 | ||||
Condition | Year | Language | Analysis type | |
, Database Validity and methodology, Drug safety, Oncology | 2022 | English | , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Retrospective database analysis | |
Predicting Hospitalization Due to COPD Exacerbations in Swedish Primary Care Patients Using Machine Learning – Based on the ARCTIC Study | ||||
Björn Ställberg 1, Karin Lisspers 1, Kjell Larsson 2, Christer Janson 3, Mario Müller 4, Mateusz Łuczko 5, Bine Kjøller Bjerregaard 6, Gerald Bacher 7, Björn Holzhauer 7, Pankaj Goyal 7, Gunnar Johansson 1 | ||||
1Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden. 2Integrative Toxicology, Karolinska Institutet, Stockholm, Sweden. 3Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden. 4Department of Data Science and Advanced Analytics, IQVIA, Frankfurt Am Main, Germany. 5Department of Data Science and Advanced Analytics, IQVIA, Warsaw, Poland. 6Department of Real World Evidence Solutions, IQVIA, Copenhagen, Denmark. 7Department of Clinical Development and Analytics, Novartis Pharma AG, Basel, Switzerland. | ||||
Journal: Int J Chron Obstruct Pulmon Dis. 2021 Mar 16;16:677-688. doi: 10.2147/COPD.S293099. eCollection 2021. Conference: IPCRG, Dublin, Ireland, Weekly series of Clinical Practice Webinars - Various Saturdays from 16th May to 27th June 2020 PMID: 33758504 PMCID: PMC7981164 DOI: 10.2147/COPD.S293099 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/33758504/ | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2021 | English | , Epidemiological study, Population Based Study | |
Developing a short-term prediction model for asthma exacerbations from Swedish primary care patients’ data using machine learning - based on the ARCTIC study Respiratory Medicine | ||||
Karin Lisspers a,*, Bj¨orn St¨allberg a, Kjell Larsson b, Christer Janson c, Mario Müller d, Mateusz Łuczko e, Bine Kjøller Bjerregaard f, Gerald Bacher g, Bj¨orn Holzhauer g, Pankaj Goyal g, Gunnar Johansson a | ||||
a Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden b Integrative Toxicology, Karolinska Institutet, Stockholm, Sweden c Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden d IQVIA, Frankfurt am Main, Germany e IQVIA, Warsaw, Poland f IQVIA, Copenhagen, Denmark g Novartis Pharma AG, Basel, Switzerland | ||||
, Sweden | ||||
Abstract: https://authors.elsevier.com/c/1d9cV_Lj95hJLT | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2021 | English | , Clinical setting: Primary care, clinical setting: Secondary care, Predictive analytics | |
Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden | ||||
Meritxell Sabidó1, Kiliana Suzart-Woischnik2, Nydjie Grimes3, Lisa M Prach4, Liwei Zhao5, Katja M Hakkarainen5 | ||||
1Merck Healthcare KGaA; 2Bayer AG; 3Biogen Netherlands B.V.; 4Novartis Pharma AG; 5Global Database Studies, IQVIA | ||||
ECTRIMS 2021, Digital, 13-15 October 2021 |
||||
, Abstract | ||||
, Finland, Sweden | ||||
Abstract: https://ectrims2021.abstractserver.com/program/#/details/presentations/466 | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Neurological disorders | 2021 | English | , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis | |
Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden | ||||
Meritxell Sabidó1, Kiliana Suzart-Woischnik2, Nydjie Grimes3, Lisa M Prach4, Liwei Zhao5, Katja M Hakkarainen5 | ||||
1Merck Healthcare KGaA; 2Bayer AG; 3Biogen Netherlands B.V.; 4Novartis Pharma AG; 5Global Database Studies, IQVIA | ||||
ECTRIMS 2021, Digital, 13-15 October 2021 |
||||
, Poster | ||||
, Finland, Sweden | ||||
Abstract: http://medpub-poster.merckgroup.com/ECTRIMS2021_INFORM_Study_Design.pdf | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Neurological disorders | 2021 | English | , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis | |
Effectiveness and safety of empagliflozin in routine care in Europe and East Asia: results from the empagliflozin comparative effectiveness and safety (EMPRISE) study | ||||
A. Karasik1 , S. Lanzinger2 , E. Chia-Hui Tan3 , D. Yabe4 , D. Jung Kim5 , W. H-H Sheu6 , C. MelzerCohen1 , R.W. Holl2 , K. Ha5 , T. Nyström7 , L. Niskanen8 , M. Linnemann Jensen9 , M.H. Kyaw10, J. Núñez11, EMPRISE EU and East Asia Study Group; | ||||
Maccabi Research & Innovation Center, Tel Aviv University, Tel Aviv, Israel, 2 Inst. for Epidemiology & Medical Biometry, Uni. of Ulm, Ulm, Germany, 3National Research Inst. of Chinese Medicine, Taipei, Taiwan, 4Dept. of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, Gifu, Japan, 5Dept. of Endocrinology & Metabolism, Ajou Uni. School of Medicine, Suwon, Republic of Korea, 6Taipei Veterans General Hospital, Taipei, Taiwan, 7Dept. of Clinical Science & Education, Södersjukhuset, Karolinska Institutet, Solna, Sweden, 8Department of Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 9 IQVIA, Copenhagen, Denmark, 10Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, USA, 11Dept. of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain | ||||
https://doi.org/10.2337/DB21-127-LB Virtual EASD 2021, 57 Annual Meeting, 27 September - 10 October 2021 |
||||
, Abstract | ||||
, Finland, Germany, Israel, Japan, South Korea, Spain, Sweden, Taiwan | ||||
Abstract: https://easddistribute.m-anage.com/from.storage?image=gOIMdpw6-DbPpKIQZ5HFcJGqJ2quHgbqFewkkUQkLblXdwzJ9kfmAYikI6R6NFu_GLAQJwEZKsC1PXU8ndyryA2 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes | 2021 | English | , Database Study, Methodology, Population Based Study | |
Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk ofcardiovascular and renal disease among type 2 diabetes patients in routinecare in europe and israel: EMPRISE study results | ||||
T Nystroem1;AKarasik2; J Nunez3; S Lanzinger4; C Melzer-Cohen2; R W Holl4;P Casajust5; E Toresson Grip6; M Carrasco7; J Foersch8; K Karlsdotter9;M Tuovinen10; R Klement11;MHKyaw12; L Niskanen | ||||
Karolinska Institutet,Department of Clinical Science and Education, Södersjukhuset, Solna, Sweden;2Tel Aviv University, Maccabi Research and Innovation Center, Tel Aviv, Israel;3University of Valencia, Department of Cardiology, Hospital Clínico Universitariode Valencia, INCLIVA, CIBER Cardiovascular, Valencia, Spain;4University of Ulm,Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany;5Trial FormSupport, Real-World Evidence, Barcelona, Spain;6Swedish Institute for HealthEconomics Quantify Research, Stockholm, Sweden;7Boehringer Ingelheim EspañaS.A., Barcelona, Spain;8Boehringer Ingelheim Pharma GmbH & Co. Kg, HP CountryMedical Affairs, Ingelheim Am Rhein, Germany;9Boehringer Ingelheim AB, Stock-holm, Sweden;10Boehringer Ingelheim KY, Secondment Boehringer Ingelheim UKHEOR Team, Helsinki, Finland;11IQVIA, Global Database Studies, Tartu, Estonia;12Boehringer Ingelheim Pharmaceutical Inc., Connecticut, United States of America;13University of Eastern Finland, Kuopio, Finland; | ||||
European Journal of Heart Failure (2021)23(Suppl. S2) 2–322doi:10.1002/ejhf.2297 |
||||
, Abstract, Article | ||||
, Finland, Germany, Israel, Spain, Sweden | ||||
Abstract: https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.2297 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes | 2021 | English | , Database Study, Meta analysis, Methodology, Population Based Study | |
Predicting hospitalization of Swedish patients due to COPD exacerbation with machine learning | ||||
Karin Lisspers, Uppsala University Christer Janson, Uppsala University Gunnar Johansson, Uppsala University Kjell Larsson, Karolinska Institutet Björn Ställberg, Uppsala University Mario Mueller, IQVIA Mateusz Luczko, IQVIA Bine Kjoeller Bjerregaard, IQVIA Stuart Fell, IQVIA Gerald Bacher, Novartis Bjorn Holzhauer, Novartis Pankaj Goyal, Novartis Pharma AG | ||||
Uppsala University, IQVIA Denmark, IQVIA Germany, IQVIA Poland | ||||
IPCRG, International Primary Care Respiratory Group Conference 2020 |
||||
, Oral presentation | ||||
, Sweden | ||||
Abstract: https://www.ipcrg.org/11516 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2020 | English | ||
Infections in patients with multiple sclerosis: A national cohort study in Sweden | ||||
Anna Castelo-Branco, Flaminia Chiesa, Simona Conte, Camilla Bengtsson , Sally Lee, Neil Minton, Steve Niemcryk, Anders Lindholm, Mats Rosenlund, Fredrik Piehl, Scott Montgomery | ||||
1.Real-world Insights, IQVIA Nordics, Solna, Sweden 2. Celgene Corporation, Summit, NJ, USA | ||||
Mult Scler Relat Disord. 2020;45:102420. [published online ahead of print, 2020 Jul 23]. |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/32736217/ | ||||
Condition | Year | Language | Analysis type | |
, Infectious disease, Neurological disorders, Patient Registries & Real-World Study Methods | 2020 | English | , Epidemiological study | |
Non-infectious comorbidity in patients with multiple sclerosis: A national cohort study in Sweden | ||||
Anna Castelo-Branco, Flaminia Chiesa, Camilla E Bengtsson , Sally Lee, Neil N Minton, Steve Niemcryk, Anders Lindholm, Mats Rosenlund, Fredrik Piehl, Scott Montgomery | ||||
1.Real-world Insights, IQVIA Nordics, Solna, Sweden 2. Celgene Corporation, Summit, NJ, USA | ||||
Mult Scler J Exp Transl Clin. 2020 Jul-Sep; 6(3): 2055217320947761. Published online 2020 Aug 14 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/32864156/ | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Neurological disorders, Patient Registries & Real-World Study Methods | 2020 | English | , Epidemiological study, Observational study, Population Based Study, Retrospective cohort analysis | |
Hospitalizations and outpatient vists (H&OV) in moderate and severe acute graft versus host disease (aGVHD) patients in Finland and Sweden | ||||
Itälä-Remes M1, Viayna E2, Nicklasson M3, Keränen M4, Thunström D5, Pfeiffer M5, Roset M2, Lara N2, Sabatelli L5 | ||||
1 Turku University Hospital, Finland 2 IQVIA, Real World Solutions, Barcelona, Spain 3 Sahlgrenska, University Hospital, Gothenburg, Sweden 4 Helsinki University Hospital, Finland 5 Incyte Biosciences International, Morges, Switzerland | ||||
ISPOR 2020 Annual European Congress. 14-18 November 2020. Milan, Italy |
||||
, Poster | ||||
, Finland, Sweden | ||||
Abstract: x | ||||
Condition | Year | Language | Analysis type | |
, Hematology, Transplant | 2020 | English | , Population Based Study, Retrospective cohort analysis | |
Osteoporosis and fracture risk associated with ICS use among Swedish COPD patients: the ARCTIC study | ||||
Christer Janson, Karin Lisspers, Björn Ställberg, Gunnar Johansson, Florian S. Gutzwiller, Karen Mezzi, Linda Mindeholm, Bine Kjoeller Bjerregaard, Leif Jorgensen, Kjell Larsson | ||||
1Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden; 2Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 3Novartis Pharma AG, Basel, Switzerland; 4Novartis Institutes for Biomedical Research (NIBR), Cambridge, USA and Basel, Switzerland; 5IQVIA Solutions, Copenhagen, Denmark; 6Intergrative Toxicology, National Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden | ||||
Eur Respir J 2020; in press (https://doi.org/10.1183/13993003.00515-2020). |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://erj.ersjournals.com/content/early/2020/08/28/13993003.00515-2020 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2020 | English | , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Retrospective database analysis | |
Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients | ||||
Björn Ställberg 1✉, Christer Janson2, Karin Lisspers1, Gunnar Johansson1, Florian S. Gutzwiller 3, Karen Mezzi3, Bine Kjoeller Bjerregaard 4, Anne Mette Tranberg Kejs4, Leif Jorgensen4 and Kjell Larsson5 | ||||
1Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden. 2Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden. 3Novartis Pharma AG, Basel, Switzerland. 4IQVIA Solutions, Copenhagen, Denmark. 5Integrative Toxicology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ?email: b.stallberg@telia.com | ||||
npj Primary Care Respiratory Medicine (2020) 30:47 ; https://doi.org/10.1038/s41533-020-00207-7 |
||||
, Article | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2020 | English | , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Retrospective database analysis | |
Bridging the Gap Between RCTs and RWE Through Endpoint Selection | ||||
Robert J LoCasale 1, Chris L Pashos 2, Ben Gutierrez 3, Nancy A Dreyer 4, Toby Collins 5, Alan Calleja 5, Michael J Seewald 6, Jonathan M Plumb 7, Johan Liwing 8, Maurille Feudjo Tepie 9, Sajan Khosla 10 | ||||
1Real World Evidence, Sanofi, Bridgewater, NJ, USA. 2AbbVie, Chicago, IL, USA. 3GSK, Philadelphia, PA, USA. 4IQVIA, Real-World Solutions, Cambridge, MA, USA. 5IQVIA, Real-World Solutions, London, UK. 6Novartis Pharma AG/Pharma Medical Affairs, Basel, Switzerland. 7Ferring Pharmaceuticals SA, St Prex, Switzerland. 8CellProtect Nordic Pharmaceuticals, Stockholm, Sweden. 9Center for Observational Research, Amgen, Cambridge, UK. 10Real-World Evidence Center of Excellence, AstraZeneca, Cambridge, UK. sajan.khosla@astrazeneca.com. | ||||
Published online 2020 Jul 6. doi: 10.1007/s43441-020-00193-5 |
||||
, Article | ||||
, Sweden, Switzerland, UK, USA | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785541/ | ||||
Condition | Year | Language | Analysis type | |
, Health status & patient reported outcomes | 2020 | English | , Real World Data, Real World Evidence | |
Cost-Effectiveness of the FreeStyle Libre System versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Treatment not Reaching Glycemic Goals in Sweden. | ||||
Jendle J, Eeg-Olofsson K, Svensson AM, Franzen S, Lamotte M, Levrat-Guillen F. | ||||
IQVIA HEOR Zaventem Brussels | ||||
American Diabetes Association’s (ADA’s) 81st Scientific Sessions. Poster presentation number 135-LB |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden | ||||
Lindmark K, Boman K, Olofsson M, Törnblom M, Levine A, Castelo-Branco A, Schlienger R, Wirta SB, Stålhammar J, Wikström G | ||||
Real-World & Analytics Solutions, IQVIA, Solna, Sweden | ||||
Clinical Epidemiology |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: https://www.dovepress.com/articles.php?article_id=44704 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2019 | English | , Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Retrospective database analysis | |
European Multi-Country Drug Utilization Study of Dulaglutide | ||||
Ayad K. Ali1, Karen E. Wells2, Mathieu Ros3, Massoud Toussi3 | ||||
1Eli Lilly and Company, Indianapolis, IN, USA 2IQVIA, Oakland, MI, USA 3IQVIA, Courbevoie, France | ||||
ICPE, Philadelphia, USA, 24-28 August 2019 |
||||
, Abstract | ||||
, France, Germany, Spain, Sweden, UK | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Drug safety | 2019 | English | , Epidemiological study, Observational study, Retrospective cohort analysis, Retrospective database analysis | |
A REVIEW OF SWEDISH HEALTH TECHNOLOGY ASSESSMENTS BASED ON INDIRECT COMPARISONS OF HOSPITAL DRUGS IN ONCOLOGY | ||||
Rongrong Zhang, Heller Vincent, Maximilian Schlueter, Ashley Pitcher | ||||
IQVIA | ||||
ISPOR Europe, Copenhagen, Denmark, 2-6 November 2019 |
||||
, Abstract | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2019 | English | , Clinical setting: Home care, Review | |
Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden. | ||||
Valachis A, Sundqvist M, Carlsson L, Li B, Chiesa F, Uhde M, Sanglier T | ||||
Department of Oncology, Faculty of Medicine & Health, ?rebro University, SE 70182 ?rebro, Sweden (Valachis) AND Real World & Analytic Solutions (RWAS), IQVIA, Stockholm, Sweden (Milica Uhde) | ||||
Future Oncol. 2019 Aug;15(23):2733-2741. doi: 10.2217/fon-2019-0160. Epub 2019 Jul 15. |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31306041 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2019 | English | , Clinical setting: hospital, Epidemiological study, Retrospective cohort analysis | |
Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study. | ||||
Larsson K1, Janson C2, Stllberg B3, Lisspers K3, Olsson P4, Kostikas K5, Gruenberger JB5, Gutzwiller FS5, Uhde M6, Jorgensen L7, Johansson G3. | ||||
Work Environment Toxicology, Karolinska Institutet, Stockholm, Sweden (Larsson) and IQVIA Sweden (Uhde) | ||||
Int J Chron Obstruct Pulmon Dis. 2019 May 13;14:995-1008. doi: 10.2147/COPD.S195382. eCollection 2019. |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31190785 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2019 | English | , Clinical setting: Primary care, Epidemiological study, Retrospective cohort analysis | |
A Survey Among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (Daratumumab) Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries | ||||
Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi | ||||
IQVIA, Courbevoie, France; Janssen EMEA, Medical Affairs, Italy; Janssen EMEA, Medical Affairs, UK | ||||
Presented at ISPE’s 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2019), August 24–28, 2019 at the Pennsylvania Convention Center, Philadelphia, PA, USA. |
||||
, Poster | ||||
, Austria, Czech, Denmark, Finland, France, Germany, Hungary, Norway, Slovakia, Spain, Sweden, Switzerland | ||||
Abstract: https://www.coodoc.com/pages/p1822-Daratumumab-ICPE-2019 | ||||
Condition | Year | Language | Analysis type | |
, Hematology, Oncology | 2019 | English | , Public Health, Survey research | |
Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and MS Pregnancy study conducted in Finland and Sweden | ||||
"Kerstin Hellwig*, Yvonne Geissbuehler2, Meritxell Sabidó3, Catrinel Popescu4, Alessandra Adamo5, Joachim Klinger6, Peter Huppke7, Asher Ornoy8, Pasi Korhonen9, Kjell-Morten Myhr10, Scott Montgomery11, Sarah Burkill11, European Interferon Beta Pregnancy Study Group" | ||||
*Katholisches Klinikum Bochum, St Josef-Hospital Universitatsklinikum, Bochum, Germany; 9StatFinn & EPID Research, Espoo, Finland | ||||
AAN, Philadelphia, USA, 4-10 May 2019 |
||||
, Oral presentation | ||||
, Europe, Finland, Nordic, Sweden | ||||
Abstract: https://n.neurology.org/content/92/15_Supplement/S49.005 | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2019 | English | , Epidemiological study, Population Based Study | |
No increased risk of spontaneous abortion and ectopic pregnancy after exposure to interferon-beta prior to or during pregnancy: Results from register-based Nordic study among women with MS | ||||
R. Juuti1, K. M. Hakkarainen 1, S. Burkill 2, Y. Geissbuehler 3, M. Sabidó 4, C. Popescu 5, A. Adamo 6, J. Hillert 2, S. Cnattingius 2, M. Artama 7, A. Verkkoniemi-Ahola 8, K.-M. Myhr 9, J. Mehtälä 1, S. Bahmanyar 2, S. Montgomery 2,10, P. Korhonen 1 and the European Interferon Beta Pregnancy Study Group | ||||
1StatFinn-EPID Research, Espoo, Finland | ||||
EAN, Oslo, Norway, June 29-2 July, 2019 |
||||
, Oral presentation | ||||
, Finland, Germany, Norway, Sweden, Switzerland, UK | ||||
Abstract: https://www.ean.org/fileadmin/_files/AbstractBook/EAN_Journal_2019_Book.pdf | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2019 | English | , Epidemiological study, Population Based Study, Retrospective database analysis | |
Prevalence of infant outcomes at birth after exposure to interferon beta prior to or during pregnancy: A register-based cohort study in Finland and Sweden among women with MS | ||||
Pia Vattulainen1, Sarah Burkill2, Yvonne Geissbuehler3, Meritxell Sabidó4, Catrinel Popescu5, Kiliana Suzart-Woischnik6, Kjell-Morten Myhr7, Scott Montgomery2,8, Pasi Korhonen1 the European Interferon Beta Pregnancy Study Group and the Nordic MS Pregnancy & Interferon Beta study group | ||||
1StatFinn-EPID Research, Espoo, Finland | ||||
ECTRIMS, Stockholm, Sweden, 11-13 September, 2019 |
||||
, Poster | ||||
, Finland, Nordic, Sweden | ||||
Abstract: https://onlinelibrary.ectrims-congress.eu/ectrims/2019/stockholm/278346/pasi.korhonen.prevalence.of.infant.outcomes.at.birth.after.exposure.to.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dmontgomery | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2019 | English | , Epidemiological study, Population Based Study, Retrospective cohort analysis | |
Assessing the Outcomes for Orphan Status or Accelerated Assessment EMA Approved Medicines: A Comparison of Health Technology Assessment in Denmark, Finland, Norway and Sweden | ||||
Falla, Edel; Pitcher, Ashley; Acs, Annabel; Heller, Vincent; Zhang, Rongrong | ||||
IQVIA, Real-World Insights, London, LON, UK IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Solna, AB, Sweden IQVIA, Real-World Insights, Stockholm, Sweden | ||||
ISPOR Europe 2019, November 5, 2019, Copenhagen, Denmark |
||||
, Poster | ||||
, Denmark, Finland, Nordic, Norway, Sweden | ||||
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(19)34089-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301519340896%3Fshowall%3Dtrue#%20 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2019 | English | , Review | |
Feasibility Assessment for Conducting a Multi-Country Post-Marketing Safety Oncology Study Using Secondary Data Sources in Europe | ||||
Wells KE, Jiang R, Tyczynski JE, Secrest M, Oliveria SA | ||||
Wells KE: IQVIA; Jiang R: Abbvie; Tyczynski JE: Abbvie; Secrest M: IQVIA; Oliveria SA: IQVIA | ||||
34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management |
||||
, Abstract | ||||
, Denmark, Finland, Germany, Norway, Sweden, UK | ||||
Condition | Year | Language | Analysis type | |
, Database Validity and methodology, Oncology, Patient Registries & Real-World Study Methods | 2018 | English | , Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis, Review | |
Real-World Use of Dulaglutide in Europe: A Multi-Country Drug Utilization Study | ||||
Ali AK, Toussi M, Phillips S, Roste M | ||||
Ali AK: Eli Lilly and Company; Toussi M: IQVIA; Phillips S: IQVIA; Roste M: IQVIA | ||||
34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management |
||||
, Abstract | ||||
, France, Germany, Spain, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Drug Utlization Study, Drug Utlization Study | 2018 | English | , Database Study, Epidemiological study | |
Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study | ||||
Johansson G, Mushnikov V, Bäckström T, Engström A, Khalid JM, Wall J, Hoti F | ||||
Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden | ||||
BMC Pulmonary Medicine (2018);18:17 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784707/ | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2018 | English | , Burden of illness, clinical setting: Secondary care, Population Based Study, Retrospective database analysis | |
Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study | ||||
Janson C, Johansson G, Ställberg B, Lisspers K, Olsson P, Keininger DL, Uhde M, Gutzwiller FS, Jörgensen L and Larsson K | ||||
Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Akademiska sjukhuset, 75185 Uppsala, Sweden|IQVIA, Stockholm, Sweden|IQVIA, Copenhagen, Denmark | ||||
Respiratory Research (2018) 19:172 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0868-y | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2018 | English | , Clinical setting: Primary care, Observational study, Population Based Study | |
Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients | ||||
Ställberg B, Janson C, Larsson K, Johansson G, Kostikas K, Gruenberger J-B, Gutzwiller F, Jorgensen F, Uhde M and Lisspers K | ||||
Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden|IQVIA, Stockholm, Sweden|IQVIA, Copenhagen, Denmark | ||||
npj Primary Care Respiratory Medicine (2018) 28:33 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.nature.com/articles/s41533-018-0101-y | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2018 | English | , Clinical setting: Primary care, Retrospective cohort analysis | |
Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR) | ||||
Larsson K, Ställberg B, Lisspers K, Telg G, Johansson G, Thuresson M, Janson C | ||||
Work Environment Toxicology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden | ||||
Respiratory Research (2018) 19:12 |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0719-x | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2018 | English | , Clinical setting: Primary care, Epidemiological study, Observational study, Population Based Study | |
Comorbidity, disease burden and mortality across age groups in a Swedish primary care asthma population: An epidemiological register study (PACEHR) | ||||
Lisspers K, Janson C, Larsson K, Johansson G, Telg G, Thuresson M, Ställberg B | ||||
Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden. | ||||
Respiratory Medicine 136 (2018) 15–20 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/29501242 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2018 | English | , Clinical setting: Primary care, Epidemiological study, Observational study, Population Based Study | |
Factors associated with lung cancer in COPD patients | ||||
Sandelin M, Mindus S, Thuresson M, Lisspers K, Ställberg B, Johanson G, Larsson K, Janson C | ||||
Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden | ||||
Int J COPD (2018) 2018:13 1833–1839 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.dovepress.com/factors-associated-with-lung-cancer-in-copd-patients-peer-reviewed-fulltext-article-COPD | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2018 | English | , Clinical setting: Primary care, Population Based Study, Retrospective cohort analysis | |
Prevalence, characteristics and management of frequently exacerbating asthma patients: an observational study in Sweden (PACEHR) | ||||
Janson C, Lisspers K, Ställberg B, Johansson G, Thuresson M, Telg G, Larsson K | ||||
Respiratory, Allergy and Sleep Research, Dept of Medical Sciences, Uppsala University, Uppsala, Sweden | ||||
European Respiratory Journal (2018) 52: 1701927 |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://erj.ersjournals.com/content/52/2/1701927 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2018 | English | , Clinical setting: Primary care, Epidemiological study, Observational study, Population Based Study | |
Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR) | ||||
Janson C, Lisspers K, Ställberg B, Johansson G, Telg G, Thuresson M, Christensen Nordahl H, Larsson K | ||||
Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, 751 85 Uppsala, Sweden | ||||
Respiratory Research (2018) 19:168 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0855-3 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2018 | English | , Clinical setting: Primary care, Cost of illness, Observational study, Population Based Study | |
Total cost of health care resource utilization for asthma patients in Sweden with different exposures to oral corticosteroids | ||||
Janson C, Lisspers K, Ställberg B, Johansson G, Thuresson M, Telg G, Christensen H, Larsson K | ||||
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Sweden | ||||
Allergy. European Journal of Allergy and Clinical Immunology, Vol. 73, no Suppl.105, p. 529-529 |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://uu.diva-portal.org/smash/record.jsf?pid=diva2%3A1260079&dswid=-316 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2018 | English | , Clinical setting: Primary care, Cost analysis | |
Different patterns of second?line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study | ||||
Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW | ||||
StatFinn & EPID Research, Espoo, Finland | ||||
Endocrinol Diabetes Metab. |
||||
, Article | ||||
, Denmark, Finland, Nordic, Norway, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354817/ | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2018 | English | , Population Based Study, Retrospective database analysis | |
Burden for Parents of Patients With Schizophrenia-A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls | ||||
Mittendorfer-Rutz E, Rahman S, Tanskanen A, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Taipale H, Tiihonen J | ||||
EPID Research Oy, Espoo, Finland | ||||
Schizophr Bull. |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://academic.oup.com/schizophreniabulletin/advance-article-abstract/doi/10.1093/schbul/sby130/5090132?redirectedFrom=fulltext | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2018 | English | , Population Based Study, Retrospective database analysis | |
Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment | ||||
Rockberg J1, Jørgensen L1, Taylor B2, Sobocki P1, Johansson G3. | ||||
1 QuintilesIMS, Solna, Sweden. 2 Amgen Inc, Thousand Oaks, CA, USA. 3 Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden. | ||||
Prev Med Rep |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374870/ | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2017 | English | , Real World Evidence | |
Extent and impact of late vs early stage COPD diagnosis in a Swedish cohort: The ARCTIC study. | ||||
Larsson K, Janson C, Ställberg B, Lisspers K, Olsson P, Kostikas K, Uhde M, Jorgensen L, Gutzwiller F S, Johansson G. | ||||
Nordic Lung Congress 2017, 10-12 May Visby Sweden |
||||
, Abstract | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2017 | English | , Real World Evidence | |
Comorbidities in Swedish COPD and non-COPD patients: ARCTIC study. | ||||
Ställberg B, Janson C, Larsson K, Johansson G, Kostikas K, Gruenberger J-B, Gutzwiller F S, Jorgensen L, Uhde M, Lisspers K. | ||||
Nordic Lung Congress 2017, 10-12 May, Visby Sweden |
||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2017 | English | , Real World Evidence | |
Description of a national pulmonary fibrosis cohort in Sweden. | ||||
Bartley K1, A Levine A2, Arnheim-Dahlstrom L2, Ferrara G3,4, Kirchgaessler K5, Linder R2, Janson C6, Sköld CM3 | ||||
1 Genentech, Inc., South San Francisco, CA, USA 2 IMS Health, Solna, Sweden 3 Karolinska University Hospital, Stockholm, Sweden 4 Karolinska Institutet, Stockholm, Sweden 5 Hoffmann-La Roche, Ltd., Basel, Switzerland 6Uppsala University, Uppsala, Sweden | ||||
British Thoracic Society Winter Meeting 2017, London |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2017 | English | , Retrospective cohort analysis | |
Predictors and diseasburden of ulcerative colitis progression in Sweden. | ||||
Stålhammar J1,Hällström P1, Agreus L2, Beydogan H3, Arnheim Dahlström L3, Skup M4, Lee W-J4 | ||||
1 Uppsala University, Uppsala, Sweden 2 Karolinska Institutet, Stockholm, Sweden 3 QuintilesIMS, Stockholm, Sweden 4 AbbVie Inc., North Chicago, USA. | ||||
UEG Barcelona September 2017 |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Immunology and Vaccination | 2017 | English | , Retrospective cohort analysis | |
Market share and switching dynamics between Etanercept and its biosimilar product in Sweden and Germany: a real-world preliminary analysis. | ||||
Alten R1, Neregård P2, Jones HE3, Meng T4, Curiale C5, Singh E6, Lucchese L7, Gossen N8, Bergman GJ9, Miglio C7 | ||||
1 Shlosspark-Klinik Teaching Hospital of the Charité, Berlin, Germany 2 Pfizer, Sollentuna, Sweden 3 Pfizer inc., Collegeville, PA, USA 4 Pfizer Pharma GmbH, Berlin, Germany 5 Pfizer, Rome, Italy 6 Pfizer Inc., Collegeville, PA, USA 7 QuintilesIMS, London, UK 8 QuintilesIMS, Frankfurt, Germany 9 QuintilesIMS, Solna, Sweden | ||||
ISPOR 20th Annual European Congress |
||||
, Germany, Nordic, Sweden | ||||
Abstract: https://www.ispor.org/Event/ProgramList/2017Glasgow?type=Poster&sess=II&acode=PSY | ||||
Condition | Year | Language | Analysis type | |
, Immunology and Vaccination, Patient Registries & Real-World Study Methods, Rheumatology | 2017 | English | , Retrospective database analysis | |
Prevalence, characteristics and management of asthma patients with frequent exacerbations ? an observational study in Sweden (PACEHR). | ||||
Janson C1, Lisspers K2, Ställberg B2, Johansson G3, Thuresson M4, Telg G4, Larsson K5. | ||||
1 Department of Medical Sciences, Respiratory Medicine, Uppsala University, Uppsala, Sweden 2 Department of Public Health and Caring Science, Family Medicine and Clinical Epidemiology, Uppsala University, Uppsala, Sweden 3 Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden. 4 Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 5 Unit of Lung and Allergy Research, National Institute of Environmental Medicine, Karolinska Institute, Stockholm | ||||
, Abstract | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2017 | English | ||
Features of severe asthma in primary care – an observational study (PACEHR). | ||||
Larsson K1, Ställberg B2, Lisspers K2, Telg G3, Johansson G4, Thuresson M3, Janson C5. | ||||
1 Unit of Lung and Allergy Research, National Institute of Environmental Medicine, Karolinska Institute, Stockholm 2 Department of Public Health and Caring Science, Family Medicine and Clinical Epidemiology, Uppsala University, Uppsala, Sweden 3 Faculty of Medicine, University of Iceland, Reykjavik, Iceland 4 Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden 5 Department of Medical Sciences, Respiratory Medicine, Uppsala University, Uppsala, Sweden | ||||
ERS International Congress, Milan, Italy, September 9-13 2017 |
||||
, Abstract | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2017 | English | ||
Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model | ||||
Gerlier L1, Hackett J2, Lawson R2, Dos Santos Mendes S3, Weil-Olivier C4, Schwehm M5, Eichner M6,7 | ||||
1 QuintilesIMS, Real-World Evidence Solutions, Zaventem, Belgium 2 AstraZeneca, Gaithersburg, MD, USA 3 AstraZeneca, Brussels, Belgium (Current affiliation: MSD, Brussels, Belgium) 4 Department of Pediatrics, University Paris VII, Paris, France 5 ExploSYS GmbH, Leinfelden-Echterdingen, Germany 6 Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany 7 Epimos GmbH, Dusslingen, Germany | ||||
JHEOR 2017;5(1):89-108 |
||||
, Article | ||||
, Australia, Belgium, Finland, France, Germany, Greece, Italy, Luxembourg, Netherlands, Poland, Portugal, Spain, Sweden, UK | ||||
Condition | Year | Language | Analysis type | |
, Immunology and Vaccination, Infectious disease, Respiratory disease | 2017 | English | , Epidemiological study, Public Health | |
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries. | ||||
Divino V., DeKoven M., Khan FA., Boye KS., Sapin H., Norrbacka K. | ||||
Lilly. IMS authors: Divino V, DeKoven M | ||||
Diabetes Ther. |
||||
, Article | ||||
, Belgium, France, Germany, Netherlands, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28070733 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2017 | English | , Retrospective database analysis | |
COMMONALITIES AND DIFFERENCES IN DATA COLLECTION ACROSS EUROPEAN SPONDYLOARTHRITIS REGISTRIES | ||||
M. L. Hetland* 1, M. Østergaard1, J. Askling2, C. Gabay3, D. Nordstrom4, O. FitzGerald5, M. Hernández Miguel6, M. Santos7 , Z. Rotar8, H. Mann9, F. Iannone10, M. J. Nissen3, E. Hauge1, J. Gomez-Reino11, F. Díaz-González12, M. Tomsic8, K. Pavelka9, F. O'Shea5, C. Sullivan5, M. van de Sande13, I. E. van der Horst-Bruinsma13, G. J. Macfarlane14, G. T. Jones14, B. Gudbjørnsson15, T. K. Kvien16 on behalf of EuroSpA Study Group | ||||
1DANBIO, Glostrup, Denmark, 2ARTIS, Stockholm, Sweden, 3SCQM, Geneva, Switzerland, 4ROB-FIN, Helsinki, Finland, 5ASRI, Dublin, Ireland, 6BIOBADASER, Barcelona, Spain, 7reuma.pt, Almada, Portugal, 8biorx.si, Ljubljana, Slovenia, 9ATTRA, Prague, Czech Republic, 10GISEA, Bari, Italy, 11BIOBADASER, Santiago, 12BIOBADASER, Santa Cruz de Tenerife, Spain, 13ARC, Amsterdam, Netherlands, 14BSRBR-AS, Aberdeen, United Kingdom, 15ICEBIO, Reykjavik, Iceland, 16NORDMARD, Oslo, Norway | ||||
EULAR, Madrid, 2017 |
||||
, Abstract | ||||
, Czech, Denmark, Finland, Ireland, Italy, Norway, Slovenia, Spain, Sweden, Switzerland | ||||
Abstract: http://ard.bmj.com/content/76/Suppl_2/656.3 | ||||
Condition | Year | Language | Analysis type | |
, Rheumatology | 2017 | English | , Epidemiological study | |
Healthcare resource utilization associated with heart failure with preserved versus reduced ejection fraction: a retrospective population-based cohort study in Sweden | ||||
Boman K, Lindmark K, Olofsson M, Stalhammar J, Bergman GJ, Tornblom M, Bruce Wirta S, Costa-Scharplatz M, Calado F, Wikstrom G | ||||
Umea University, Research Unit, Medicine, Skellefteå, Department of Public Health and Clinical Medicine, Umea, Sweden|QuintilesIMS, Solna, Sweden | ||||
European Journal of Heart Failure (2017); 19 (Suppl. S1): 5–601 |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.833 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2017 | English | , Clinical setting: Primary care, clinical setting: Secondary care, Population Based Study, Retrospective database analysis | |
Adjusting for Unobserved Disease Severity Using Individuals as Their Own Controls - An Example from a Schizophrenia Study | ||||
Mehtälä J, Majak M, Taipale H, Tanskanen A, Tiihonen J, Mittendorfer-Rutz E, Sermon J, Leval A, Hoti F | ||||
EPID Research, Espoo, Finland | ||||
Pharmacoepidemiology and Drug Safety (2017);26 (Suppl. 2): pp 3-636 |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: https://onlinelibrary.wiley.com/doi/epdf/10.1002/pds.4275 | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2017 | English | , Observational study | |
Management of Patients with Heart Failure with Preserved Versus Reduced Ejection Fraction: A Retrospective Population-Based Cohort Study in Sweden | ||||
Stålhammar J, Boman K, Olofsson M, Wikström G, Jonasdottir Bergman G, Törnblom M, Wintzell V, Bruce Wirta S, Proenca CC, Schlienger R, Lindmark K | ||||
Uppsala University, Department of Public Health and Caring Sciences - Uppsala - Sweden | ||||
European Journal of Heart Failure ( 2017 );19(Suppl. S1):54 |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Abstract: https://esc365.escardio.org/Congress/Heart-Failure-2017-4th-World-Congress-on-Acute-Heart-Failure/Poster-Session-1-Chronic-heart-failure/152428-management-of-patients-with-heart-failure-with-preserved-versus-reduced-ejection-fraction-a-retrospective-population-based-cohort-study-in-sweden | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2017 | English | , Clinical setting: Primary care, clinical setting: Secondary care, Population Based Study, Retrospective database analysis | |
Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study | ||||
Strongman H, Korhonen P, Williams R, Bahmanyar S, Hoti F, Christopher S, Majak M, Kool-Houweling L, Linder M, Dolin P, Heintjes EM | ||||
EPID Research, Espoo, Finland | ||||
BMJ Open Diab Res Care (2017);5: p. e000364-e000364 |
||||
, Article | ||||
, Finland, Netherlands, Sweden, UK | ||||
Abstract: https://drc.bmj.com/content/5/1/e000364 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2017 | English | , Epidemiological study, Retrospective database analysis | |
Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia | ||||
Taipale H, Mittendorfer-Rutz E, Alexanderson K, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Tiihonen J | ||||
Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden | ||||
Schizophrenia Research (2017) pii: S0920-9964(17)30762-4. |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.sciencedirect.com/science/article/pii/S0920996417307624 | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2017 | English | , Population Based Study, Prospective study | |
Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia | ||||
Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Taipale H | ||||
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden | ||||
JAMA Psychiatry. (2017) 74(7):686-693 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2629295 | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2017 | English | , Population Based Study, Prospective study | |
Drug Treatment Patterns in Patients Newly Diagnosed with Heart Failure: A Retrospective Population-Based Cohort Study in Sweden | ||||
Wikström G, Lindmark K, Olofsson M, Stålhammar J, Jonasdottir Bergman G, Johansson S, Wintzell V., Bruce Wirta S, Balas B, Boman K | ||||
Uppsala University, Institute for Medical Sciences - Uppsala - Sweden||IMS Health Sweden, Stockholm, Sweden | ||||
European Journal of Heart Failure ( 2017 ) 19 ( Suppl. S1 ), 55 |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: https://esc365.escardio.org/Congress/Heart-Failure-2017-4th-World-Congress-on-Acute-Heart-Failure/Poster-Session-1-Chronic-heart-failure/152433-drug-treatment-patterns-in-patients-newly-diagnosed-with-heart-failure-a-retrospective-population-based-cohort-study-in-sweden | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2017 | English | , Population Based Study, Retrospective cohort analysis | |
Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment | ||||
Rockberg J, Jörgensen L, Taylor B, Sobocki P, Johansson G | ||||
QuintilesIMS, Solna, Sweden | ||||
Preventive Medicine Reports, (2017) vol 6, 203-206 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.sciencedirect.com/science/article/pii/S2211335517300438?via%3Dihub#! | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2017 | English | , Population Based Study, Retrospective cohort analysis | |
Economic burden of COPD in a Swedish cohort: the ARCTIC study | ||||
Lisspers K, Larsson K, Johansson G, Janson C, Costa-Scharplatz M, Gruenberger JB, Uhde M, Jorgensen L, Gutzwiller FS, Ställberg B | ||||
Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala|IQVIA, Stockholm, Sweden|IQVIA, Copenhagen, Denmark | ||||
Int J COPD (2018) 2018:13, 275-285 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.dovepress.com/economic-burden-of-copd-in-a-swedish-cohort-the-arctic-study-peer-reviewed-article-COPD | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2017 | English | , Cost of illness, Retrospective cohort analysis | |
Gender and economic aspects of COPD in a Swedish cohort: The ARCTIC study | ||||
Lisspers K, Larsson K, Jansson C, Ställberg B, Gutzwiller F S, Mezzi K, Udhe M, Jorgensen L, Johansson G | ||||
Uppsala University, Uppsala, Sweden|IQVIA, Stockholm, Sweden|IQVIA, Copenhagen, Denmark | ||||
European Journal of Respiratory Research (2017) 50: PA932 |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://erj.ersjournals.com/content/50/suppl_61/PA932 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2017 | English | , Clinical setting: Primary care, Cost of illness, Epidemiological study, Observational study | |
Extent and Impact of Late Versus Early COPD Diagnosis in Women in the Swedish ARCTIC Study | ||||
Lisspers K, Larsson K, Jansson C, Ställberg B, Gutzwiller F S, Mezzi K, Udhe M, Jorgensen L, Johansson G | ||||
Uppsala University, Uppsala, Sweden|IQVIA, Stockholm, Sweden|IQVIA, Copenhagen, Denmark | ||||
ATS 2017 |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A4705 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2017 | English | , Clinical setting: Primary care, Cost analysis, Epidemiological study, Observational study | |
Characteristics of asthma patients with frequent exacerbations ? an observational study in Sweden | ||||
Janson C, Lisspers K, Ställberg B, Johansson G, Thuresson M, Telg G, Larsson K | ||||
Uppsala University, Uppsala, Sweden | ||||
European Journal of Respiratory Research (2017) 50: PA3870 |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://erj.ersjournals.com/content/50/suppl_61/PA3870 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2017 | English | , Population Based Study, Retrospective cohort analysis | |
Features of severe asthma in primary care – an observational study | ||||
Larsson K, Ställberg B, Lisspers K, Telg G, Johansson G, Thuresson M, Janson C | ||||
Department of Environmental Medicine, Karolinska Institutet, Solna, Sweden | ||||
European Journal of Respiratory Research (2017) 50: PA1601 |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://erj.ersjournals.com/content/50/suppl_61/PA1601 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2017 | English | , Clinical setting: Primary care, Epidemiological study, Observational study, Population Based Study | |
Cross-cultural validation of Lupus Impact Tracker in five European clinical practice settings | ||||
Schneider M, Mosca M, Pego-Reigosa JM, Gunnarsson I, Maurel F, Garofano A, Perna A, Porcasi R, Devilliers H | ||||
Policlinic of Rheumatology, Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany. Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy. Department of Rheumatology, Complexo Hospitalario Universitario de Vigo, Ourense y Pontevedra, Spain. Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Solna, Sweden. HEOR, Real-World Evidence Solutions (RWES) unit, IMS Health, Paris-La Défense, France. Global Specialty Pharma Franchise, GlaxoSmithKline; Services Unlimited, Brentford, UK. Immunology Medical Department, GlaxoSmithKline spa, Verona, Italy. Department of Internal Medicine and Systemic Diseases, University Hospital of Dijon, 5bis INSERM U866 5ter INSERM CIC-EC 1432, Dijon, France. | ||||
Rheumatology (Oxford). 2017 May 1;56(5):818-828 |
||||
, Article | ||||
, France, Germany, Italy, Spain, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28204765 | ||||
Condition | Year | Language | Analysis type | |
, Immunology and Vaccination, Rheumatology | 2017 | English | , Retrospective Field Study | |
Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. | ||||
Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1. | ||||
1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden. | ||||
Clinical Epidemiology |
||||
, Article | ||||
, Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK | ||||
Abstract: http://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pmc/articles/PMC4887072/ | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2016 | English | , Literature Review | |
Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden | ||||
Lind M1,2, Matsson PO3, Linder R4, Svenningsson I5, Jørgensen L6, Ploug UJ7, Gydesen H7, Dorkhan M8, Larsen S8, Johansson G9. | ||||
1Department of Medicine, NU-Hospital Group, Trollhättan/Uddevalla, Sweden. lind.marcus@telia.com. 2Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden. lind.marcus@telia.com. 3Domnarvet VC, Borlänge, Sweden. 4Pygargus, Stockholm, Sweden. 5Research and Development Unit, Primary Health Care, Närhälsan, Vänersborg, Sweden. 6IMS Health, Stockholm, Sweden. 7Novo Nordisk A/S, Søborg, Denmark. 8Novo Nordisk Scandinavia AB, Malmö, Sweden. 9Department of Caring Sciences and Family Medicine, Uppsala University, Uppsala, Sweden. | ||||
Diabetes Ther |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900983/ | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2016 | English | , Retrospective cohort analysis | |
Population-based study of giant cell tumor of bone in Sweden (1983-2011). | ||||
Amelio JM1, Rockberg J2, Hernandez RK3, Sobocki P4, Stryker S5, Bach BA3, Engellau J6, Liede A5 | ||||
1Amgen Ltd. Uxbridge, UK. Electronic address: justyna.amelio@amgen.com. 2Pygargus/IMS Health, Stockholm, Sweden. 3Amgen Inc. Thousand Oaks, CA, USA. 4Pygargus/IMS Health, Stockholm, Sweden; Karolinska Institutet, Stockholm, Sweden. 5Amgen Inc. South San Francisco, CA, USA. 6Lund University, Lund, Sweden. | ||||
Cancer Epidemiol |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://www.cancerepidemiology.net/article/S1877-7821(16)30039-X/abstract | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2016 | English | , Real World Evidence | |
Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden. | ||||
Hallberg S1, Banefelt J1, Fox KM2, Mesterton J1,3, Johansson G4, Levin LÅ5, Sobocki P3,6, Gandra SR7. | ||||
1Quantify Research, Stockholm, Sweden. 2Strategic Healthcare Solutions, LLC, Baltimore, MD, USA. 3LIME/Medical Management Centre, Karolinska Institute, Stockholm, Sweden. 4Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden. 5Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 6IMS Health, Stockholm, Sweden. 7Amgen Inc., Thousand Oaks, CA, United States. | ||||
Int J Clin Pract |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819716/ | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2016 | English | , Epidemiological study | |
Exposure to heart failure treatments in newly diagnosed patients in Sweden | ||||
G Wikstrom1, K Boman2, M Olofsson2, K Lindmark3, R Lahoz4, S Corda4, V Wintzell5, R Linder5, A Gondos6, J Stalhammar7, | ||||
1Uppsala University, Institute for Medical Sciences - Uppsala - Sweden, 2Umea University, Department of Public Health and Clinical Medicine - Umea - Sweden, 3Umea University, Heart Centre, Department of Public Health and Clinical Medicine - Umea - Sweden, 4Novartis Pharma AG - Basel - Switzerland, 5IMS Health Sweden - Stockholm - Sweden, 6IMS Health Germany - Berlin - Germany, 7Uppsala University, Department of Public Health and Caring Sciences - Uppsala - Sweden | ||||
European Journal of Heart Failure, 2016, Vol. 18, 48-48 p. |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://onlinelibrary.wiley.com/doi/10.1002/ejhf.539/epdf | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2016 | English | , Real World Evidence | |
Dosing of heart failure treatments in newly diagnosed unselected patients in Sweden: compliance with European society of cardiology guidelines | ||||
G Wikstrom1, K Boman2, M Olofsson2, K Lindmark3, R Lahoz4, S Corda4, V Wintzell5, R Linder5, A Gondos6, J Stalhammar7 | ||||
1Uppsala University, Institute for Medical Sciences - Uppsala - Sweden, 2Umea University, Research Unit, Medicine and Geriatric, Skellefteå County Hospital, Department of Public Health - Umea - Sweden, 3Umea University, Heart Centre, Department of Public Health and Clinical Medicine - Umea - Sweden, 4Novartis Pharma AG - Basel - Switzerland, 5IMS Health Sweden - Stockholm - Sweden, 6IMS Health Germany - Berlin - Germany, 7Uppsala University, Department of Public Health and Caring Sciences - Uppsala - Sweden | ||||
European Journal of Heart Failure |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://onlinelibrary.wiley.com/doi/10.1002/ejhf.539/epdf | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2016 | English | , Real World Evidence | |
Recent trends in diagnostic work-up among unselected patients newly diagnosed with heart failure: a Swedish population-based study | ||||
J Stalhammar1, K Boman2, M Olofsson2, K Lindmark3, R Lahoz4, S Corda4, V Wintzell5, R Linder5, A Gondos6, G Wikstrom7 | ||||
1Uppsala University, Department of Public Health and Caring Sciences - Uppsala - Sweden, 2Umea University, Research Unit, Medicine and Geriatric, Skellefteå County Hospital, Department of Public Health - Umea - Sweden, 3Umea University, Heart Centre, Department of Public Health and Clinical Medicine - Umea - Sweden, 4Novartis Pharma AG - Basel - Switzerland, 5IMS Health Sweden - Stockholm - Sweden, 6IMS Health Germany - Berlin - Germany, 7Uppsala University, Institute for Medical Sciences - Uppsala - Sweden | ||||
European Journal of Heart Failure |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://onlinelibrary.wiley.com/doi/10.1002/ejhf.539/epdf | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2016 | English | , Real World Evidence | |
A description of unselected patients with heart failure: a swedish population-based study | ||||
J Stalhammar1, K Boman2, M Olofsson2, K Lindmark3, R Lahoz4, S Corda4, V Wintzell5, R Linder5, A Gondos6, G Wikstrom7 | ||||
1Uppsala University, Department of Public Health and Caring Sciences - Uppsala - Sweden, 2Umea University, Research Unit, Medicine and Geriatric, Skellefteå County Hospital, Department of Public Health - Umea - Sweden, 3Umea University, Heart Centre, Department of Public Health and Clinical Medicine - Umea - Sweden, 4Novartis Pharma AG - Basel - Switzerland, 5IMS Health Sweden - Stockholm - Sweden, 6IMS Health Germany - Berlin - Germany, 7Uppsala University, Institute for Medical Sciences - Uppsala - Sweden | ||||
European Journal of Heart Hailure |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://onlinelibrary.wiley.com/doi/10.1002/ejhf.539/epdf | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2016 | English | , Real World Evidence | |
The economic burden of COPD in a Swedish cohort: The ARCTIC study | ||||
Karin Lisspers1, Kjell Larsson2, Gunnar Johansson1, Christer Janson1, Madlaina Costa-Scharplatz3, Jean-Bernard Gruenberger3, Milica Uhde4, Leif Jorgensen4, Patrik Sobocki2,4, Björn Ställberg2 4 | ||||
1Uppsala University, Sweden, 2Karolinska Institutet, Sweden, 3Novartis Pharma AG, Sweden, 4IMS Health | ||||
NPJ Primary Care Respiratory Medicine |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://www.nature.com/npjpcrm/abstracts | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Real World Evidence | |
The prevalence of comorbidities in Swedish COPD and non-COPD patients: The ARCTIC study | ||||
Bjorn Stallberg1, Christer Janson1, Kjell Larsson2, Gunnar Johansson1, Konstantinos Kostikas3, Jean-Bernard Gruenberger3, Leif Jorgensen4, Patrik Sobocki2 4, Karin Lisspers1 | ||||
1Uppsala University, Sweden, 2Karolinska Institutet, Sweden, 3Novartis Pharma AG, Sweden, 4IMS Health Sweden | ||||
NPJ Primary Care Respiratory Medicine |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://www.nature.com/npjpcrm/abstracts | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Real World Evidence | |
ICS and risk of pneumonia in Swedish COPD patients: ARCTIC study | ||||
Christer Janson1, Gunnar Johansson1, Björn Ställberg1, Karin Lisspers1, Petter Olsson2, Dorothy Keininger2, Leif Jorgensen3, Patrik Sobocki3 4, Kjell Larsson4 | ||||
1Uppsala University, Sweden, 2Novartis Pharma AG, Sweden, 3IMS Health, Sweden, 4Karolinska Institutet, Sweden | ||||
NPJ Primary Care Respiratory Medicine |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://www.nature.com/npjpcrm/abstracts | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Real World Evidence | |
Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting. | ||||
Hasvold P1,2, Thuresson M3, Sundström J4, Hammar N5,6, Kjeldsen SE7,8, Johansson G9, Holme I10, Bodegård J11. | ||||
1AstraZeneca, 151 85, Södertälje, Sweden. paal.hasvold@astrazeneca.com. 2Medical Faculty, University of Oslo, 0424, Oslo, Norway. paal.hasvold@astrazeneca.com. 3Statisticon AB, 753 22, Uppsala, Sweden. 4Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, 751 05, Uppsala, Sweden. 5Institute of Environmental Medicine, Karolinska Institute, 171 77, Stockholm, Sweden. 6Medical Evidence and Observational Research, AZ R&D, Mölndal, Sweden. 7Medical Faculty, University of Oslo, 0424, Oslo, Norway. 8Department of Cardiology, Oslo University Hospital, Oslo, Norway. 9Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, 751 05, Uppsala, Sweden. 10Department of Sports Medicine, Norwegian School of Sport Sciences, PO Box 4014, Ulleval Stadion, 0806, Oslo, Norway. 11AstraZeneca, 151 85, Södertälje, Sweden. | ||||
Clin Drug Investig |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761013/ | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2016 | English | , Real World Evidence | |
Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence. | ||||
Rockberg J1, Amelio JM2, Taylor A2, Jörgensen L1, Ragnhammar P3, Hansson J4. | ||||
1Pygargus AB/IMS Health Sweden AB, Pyramidvägen 7, Solna, Sweden 169 56. 2Amgen Inc, Uxbridge Business Park, Uxbridge, UK UB8 1DH. 3Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden 171 76. 4Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden 171 76. johan.hansson@ki.se. | ||||
Int J Cancer |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/27563839 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2016 | English | , Epidemiological study, Real World Evidence | |
COPD Patients Initiating Roflumilast in Sweden, Germany and the United States: Findings from the Roflumilast PASS Study | ||||
Hoti F, Mushnikov V, Mehtälä J, et al. | ||||
32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 2016; Dublin, Ireland |
||||
, Abstract | ||||
, Germany, Nordic, Sweden, USA | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Real World Evidence | |
Patterns of Roflumilast Use for the Treatment of COPD Across Three Distinct Populations: Findings from the Roflumilast PASS Study | ||||
Knox C, Mountford W, Kaufman E, et al. | ||||
32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 2016; Dublin, Ireland |
||||
, Abstract | ||||
, Germany, Sweden, USA | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Epidemiological study, Real World Evidence | |
Clinical and economic factors associated with spirometry-diagnosed COPD in the Swedish ARCTIC study | ||||
Gunnar Johansson (1), Gunnar Johansson, Kjell Larsson, Björn Ställberg, Karin Lisspers, Petter Olsson, Jean-Bernard Gruenberger, Leif Jorgensen, Patrik Sobocki, Christer Janson | ||||
1 Uppsala, Sweden | ||||
Eur Respir J |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://www.ers-education.org/publications/erj.aspx?idParent=151806 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Real World Evidence | |
The economic burden of COPD in a Swedish cohort: The ARCTIC study | ||||
Karin Lisspers (1), Karin Lisspers, Kjell Larsson, Gunnar Johansson, Christer Janson, Madlaina Costa-Scharplatz, Jean-Bernard Gruenberger, Milica Uhde, Leif Jorgensen, Patrik Sobocki, Björn Ställberg | ||||
(1) Gagnef, Sweden | ||||
Eur Respir J European Respiratory Society International Congress; 2016; London, UK |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://www.ers-education.org/events/international-congress/london-2016.aspx?idParent=151806 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Real World Evidence | |
Evaluation of Swedish Integrated Electronic Health Records and Register Health Care Data to Support Interpretation of a Reference Population in Asthma Clinical Trials | ||||
Stefan Franzen , PhD 1 , Gunnar Magnusson , PhD 2 , Gunilla Telg , Mrs 3 , Urban Olsson , BSc 4 , Christer Janson , MD PhD 5 , Kjell Larsson , Professor 6 , Max Petzold , PhD 7 , Mats Sundgren , PhD 8 | ||||
1 Registercentrum, Gothenburg, Sweden 2 AstraZeneca, Gothenburg, Sweden 3 AstraZeneca Nordic-Baltic, Södertälje, Sweden 4 Statisticon, Uppsala, Sweden 5 Dept Medical Sciences: Respiratory, allergy and sleep research, Uppsala, Sweden 6 Karolinska Institutet, Stockholm, Sweden 7 Centre for Applied Biostatistics, Gothenburg, Sweden 8 AstraZeneca, Gothenburg, Sweden | ||||
American Thoracic Society |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A1746 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Real World Evidence | |
Comorbidities of Swedish patients diagnosed with chronic obstructive pulmonary disease (COPD) and/or asthma | ||||
Gunnar Johansson, Christer Janson, Marianka Van Der Tol, Rinat Ariely, Gudrun Bergman, Milica Uhde, Patrick Sobocki, Hicham Benhaddi. | ||||
British Thoracic Society Winter Meeting 2016, London |
||||
, Abstract | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Real World Evidence | |
Extracting dosage per day from free-text medication prescriptions | ||||
Törnblom M, Bergman G, Jørgensen L, Fackle-Fornius E, Rosenlund M. | ||||
ISPOR 19th annual European Congress, Vienna 2016 |
||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Database Validity and methodology | 2016 | English | , Real World Data | |
Overall survival and intermediate outcomes among Scandinavian non-small cell lung cancer patients: the SCAN-LEAF study | ||||
Simon Ekman (MD, PhD)1, Jens Benn Sørensen (MD, DMSc, MPA)2, Julia Rockberg (MSc, PhD)3, Martin Sandelin (MD, PhD)4, Melinda Manley Daumont (PhD)5, Patrik Sobocki (PhD)3, Peter Klint (PhD)6, Han-Yao Huang (PhD)7, Jenny Svärd (MSc, PhD)3, Oana Cristina Chirita (MPharm, MSc)8, Leif Jörgensen (MSc)3, Maria Planck (MD, PhD)9 | ||||
1. Karolinska University Hospital, Stockholm, Sweden 2. Rigshospitalet, Copenhagen, Denmark 3. Pygargus/IMS Health, Solna, Sweden 4. Uppsala University, Uppsala, Sweden 5. Bristol-Myers Squibb, Paris, France 6. Bristol-Myers Squibb, Solna, Sweden 7. Bristol-Myers Squibb, Pennington, NJ, USA 8. Bristol-Myers Squibb, Uxbridge, UK 9. Lund University, Lund, Sweden | ||||
IASLC 17th World Conference on Lung Cancer, Vienna 2016 |
||||
, Abstract | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2016 | English | , Epidemiological study, Real World Evidence | |
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. | ||||
Peyrin-Biroulet L1, Van Assche G2, Sturm A3, Gisbert JP4, Gaya DR5, Bokemeyer B6, Mantzaris GJ7, Armuzzi A8, Sebastian S9, Lara N10, Lynam M10, Rojas-Farreras S10, Fan T11, Ding Q11, Black CM11, Kachroo S11. | ||||
1Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com. 2Division of Gastroenterology, University Hospitals Leuven, Leuven Belgium. 3Department of Gastroenterology, DRK Kliniken Berlin I Westend, Berlin, Germany. 4Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. 5Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, United Kingdom. 6Gastroenterology Practice, Minden, Germany. 7Department of Gastroenterology, Evangelismos Hospital, Athens, Greece. 8IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy. 9Gastroenterology and IBD Unit, Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom. 10IMS Health, Real World Evidence Solutions, Spain. 11Merck & Co., Inc., Kenilworth, NJ, United States | ||||
Dig Liver Dis. 2016 Jun;48(6):601-7. |
||||
, Article | ||||
, Belgium, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, UK | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders | 2016 | English | , Burden of illness, Patient questionnaire, Survey research | |
Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study | ||||
Van Assche G1, Peyrin-Biroulet L2, Sturm A3, Gisbert JP4, Gaya DR5, Bokemeyer B6, Mantzaris GJ7, Armuzzi A8, Sebastian S9, Lara N10, Lynam M10, Rojas-Farreras S10, Fan T11, Ding Q11, Black CM11, Kachroo S11. | ||||
1Division of Gastroenterology, University Hospitals Leuven, Leuven, Belgium. Electronic address: gert.vanassche@uzleuven.be. 2Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France. 3Department of Gastroenterology, DRK Kliniken Berlin I Westend, Berlin, Germany. 4Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica and Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. 5Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, UK. 6Gastroenterology Practice, Minden, Germany. 7Department of Gastroenterology, Evangelismos Hospital, Athens, Greece. 8IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy. 9Gastroenterology and IBD Unit, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK. 10IMS Health, Real World Evidence Solutions, Barcelona, Spain. 11Merck & Co., Inc., Rahway, NJ, United States. | ||||
Dig Liver Dis. 2016 Jun;48(6):592-600 |
||||
, Article | ||||
, Belgium, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, UK | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders | 2016 | English | , Burden of illness, Patient questionnaire | |
Evaluation of the use of Swedish integrated electronic health records and register health care data as support clinical trials in severe asthma: the PACEHR study. | ||||
Franzén S1, Janson C2, Larsson K3, Petzold M4, Olsson U5, Magnusson G6, Telg G7, Colice G8, Johansson G9, Sundgren M10,11. | ||||
1 Register Centrum, Gothenburg, Sweden. 2 Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden. 3 Department of Environmental Medicine, Karolinska Institute, Solna, Sweden. 4 Centre for Applied Biostatistics, University Gothenburg, Gothenburg, Sweden. 5 Statisticon AB, Uppsala, Sweden. 6 AstraZeneca, Gothenburg, Sweden. 7 AstraZeneca Nordic-Baltic, Södertälje, Sweden. 8 AstraZeneca, Gaithersburg, USA. 9 Public Health and Caring Science, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden. 10 AstraZeneca, Gothenburg, Sweden. mats.sundgren@astrazeneca.com. 11 Biometrics and Information Science, AstraZeneca, Gothenburg, SE-431 83, Mölndal, Sweden. mats.sundgren@astrazeneca.com. | ||||
Respir Res |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109788/ | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Real World Evidence | |
Treatment and dosing patterns among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Europe. | ||||
Kirsi Norrbacka; Victoria Divino; Mitch DeKoven; Kristina Secnik Boye | ||||
Lilly. IMS authors: Divino V, DeKoven M | ||||
European Association for the Study of Diabetes 52nd annual meeting |
||||
, Poster | ||||
, Belgium, France, Germany, Netherlands, Sweden | ||||
Abstract: https://www.easd.org/virtualmeeting/home.html#!resources/treatment-and-dosing-patterns-among-patients-with-type-2-diabetes-initiating-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-in-europe-5ef3fe71-7e5d-4bdd-8b32-b4187d2a9aac | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2016 | English | , Retrospective database analysis | |
Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries | ||||
Korhonen P, Heintjes E M, Williams R, Hoti F, Christopher S, Majak M, Kool-Houweling L, Strongman H, Linder M, Dolin P, Bahmanyar S | ||||
EPID Research Ltd, Espoo, Finland | ||||
BMJ (2016);354:i3903 |
||||
, Article | ||||
, Finland, Netherlands, Sweden, UK | ||||
Abstract: https://researchonline.lshtm.ac.uk/4646203/1/Pioglitazone%20use%20and%20risk_GOLD%20VoR.pdf | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2016 | English | , Population Based Study, Retrospective cohort analysis | |
Use of Contraindicated Drugs in Pediatric Outpatients in the Nordic Countries | ||||
Prami T, Långström D, Iso-Mustajärvi I, Sandler N | ||||
EPID Research, Espoo, Finland | ||||
Pharmacoepidemiology and Drug Safety (2016):25 (S3): pp. 3-679 |
||||
, Abstract | ||||
, Denmark, Finland, Norway, Sweden | ||||
Abstract: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.4070 | ||||
Condition | Year | Language | Analysis type | |
, Pediatrics | 2016 | English | , Retrospective database analysis | |
Dosing of heart failure treatments in newly diagnosed unselected patients in sweden: compliance with european society of cardiology guidelines | ||||
Wikström G, Boman K, Olofsson M, Lindmark K, Lahoz R, Corda S, Wintzell V, Linder R, Gondos A, Stalhammer J | ||||
Uppsala University, Institute for Medical Sciences, Uppsala, Sweden|IMS Health Sweden, Stockholm, Sweden | ||||
European Journal of Heart Failure. (2016) 18:341-341 |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Abstract: https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.539 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2016 | English | , Clinical setting: Primary care, clinical setting: Secondary care, Population Based Study | |
Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden | ||||
Banefelt J, Hallberg S, Fox K M, Mesterton J, Paoli C J, Johansson G, Levin L-Å, Sobocki P, Gandra S R | ||||
Quantify Research Stockholm Sweden|IMS Health Stockholm Sweden | ||||
Eur J Health Econ (2016) 17: 1117 |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: https://link.springer.com/article/10.1007/s10198-015-0749-y | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2016 | English | , Cost of illness, Population Based Study, Retrospective cohort analysis | |
Comorbidities of swedish patients diagnosed with chronic obstructive pulmonary disease (COPD) and/or asthma | ||||
Johansson G, Janson C, Van Der Tol M, Ariely R, Bergman G, Uhde M, Sobocki P, Benhaddi H | ||||
Uppsala University, Uppsala, Sweden|IMS Health, Solma, Sweden | ||||
Thorax (2016) 71:A158-A159 |
||||
, Poster | ||||
, Sweden | ||||
Abstract: https://thorax.bmj.com/content/71/Suppl_3/A158.2 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Population Based Study, Retrospective cohort analysis | |
Comorbidity and mortality in Swedish asthma patients 2006 – 2013 - An observational register study (PACEHR) | ||||
Lisspers K, Janson C, Larsson K, Johansson G, Telg G, Stratelis G, Thuresson M, Stallberg | ||||
Public Health and Caring Sciences, Family Medicine and Preventive Medicne, Uppsala University, Uppsala, Sweden | ||||
European Journal of Respiratory Research (2016) 48: PA845 |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://erj.ersjournals.com/content/48/suppl_60/PA845 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2016 | English | , Epidemiological study, Observational study | |
Cost-effectiveness analysis of a low-dose contraceptive levonorgestrel intrauterine system in Sweden | ||||
Henry N1, Hawes C1, Lowin J1, Lekander I2, Filonenko A3, Kallner HK4. | ||||
1IMS Health, London, UK. 2Bayer AB, Solna, Sweden. 3Bayer Pharma AG, Berlin, Germany. 4Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden. | ||||
Acta Obstet Gynecol Scand. 2015 Aug;94(8):884-90 |
||||
, Article | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Womens Health | 2015 | English | , Cost effectiveness | |
COST-EFFECTIVENESS OF DULAGLUTIDE 1.5MG ONCE WEEKLY FOR THE TREATMENT OF PATIENTS WITH TYPE TWO DIABETES MELLITUS IN SWEDEN | ||||
Raibouaa A1, Borgeke H2, Alexiou D3, Lowin J3, Norrbacka K4 | ||||
1Eli Lilly and Company Limited, Windlesham, Surrey, UK, 2Eli Lilly Sweden AB, Solna, Sweden, 3IMS Health, London, UK, 4Eli Lilly and Company, Helsinki, Finland | ||||
ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
2015 | English | |||
Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden. | ||||
Banefelt J1, Hallberg S2, Fox KM3, Mesterton J2,4, Paoli CJ5, Johansson G6, Levin LÅ7, Sobocki P4,8, Gandra SR5. | ||||
1Quantify Research, Hantverkargatan 8, 112 21, Stockholm, Sweden. jonas.banefelt@quantifyresearch.com. 2Quantify Research, Hantverkargatan 8, 112 21, Stockholm, Sweden. 3Strategic Healthcare Solutions, LLC, Baltimore, MD, USA. 4LIME/Medical Management Centre, Karolinska Institute, Stockholm, Sweden. 5Amgen Inc., Thousand Oaks, CA, USA. 6Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden. 7Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 8IMS Health, Stockholm, Sweden. | ||||
Eur J Health Econ |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://link.springer.com/article/10.1007%2Fs10198-015-0749-y | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2015 | English | , Real World Evidence | |
Incidence Trends in the Diagnosis of Giant Cell Tumor of Bone in Sweden Since 1958. | ||||
Rockberg J1, Bach BA2, Amelio J3, Hernandez RK4, Sobocki P1, Engellau J5, Bauer HC6, Liede A7. | ||||
1IMS Health (Pygargus), Sveavägen 155, SE-113 46, Stockholm, Sweden. 2Amgen Inc., One Amgen Center Drive, MS 38-2-B, Thousand Oaks, CA 91320-1799. 3Amgen Ltd, 1 Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, England. 4Amgen Inc., One Amgen Center Drive, MS 24-2-A, Thousand Oaks, CA 93120-1799. 5Lund University, SE-221 85 Lund, Sweden. 6Karolinska Universitetssjukhuset, Solna, A2:07,171 76 Stockholm, Sweden. 7Center for Observational Research, Amgen, Inc., 1120 Veterans Boulevard, ASF3, South San Francisco, CA 94080. E-mail address: aliede@amgen.com. | ||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://jbjs.org/content/97/21/1756.long | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2015 | English | , Real World Evidence | |
Estimating Rates of Cardiovascular Death Using Royston-Parmar Survival Models: An Example in a High Risk Patient Population in Sweden | ||||
Julia Sandberg1, Leif Jorgensen1, Mark Danese2, Benjamin Taylor3, Ryan Kilpatrick4 and Patrik Sobocki1 | ||||
1 IMS Health Sweden, 2 Outcomes Insights Inc. CA USA, 3 Amgen Inc. CA USA, 4 GSK NC USA | ||||
Circulation |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://circ.ahajournals.org/content/131/Suppl_1/AP233.abstract | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2015 | English | , Real World Evidence | |
Characteristics, Referral and Treatment Patterns of Patients Diagnosed with Psoriatic Arthritis ? A Retrospective Cohort Study Based in Sweden | ||||
J. Rockberg1, M. Mittal2, A. Joshi2, Y. Bao2, J. Anderson3, R. Linder1, J. Stålhammar4, U. Lindqvist5 | ||||
1Real World Evidence Solutions & HEOR, Pygargus AB/IMS Health, Stockholm, Sweden 2Health Economics and Outcomes Research (HEOR) 3Immunology Clinical Development, AbbVie Inc, Chicago, United States 4Department of Public health and Caring Sciences; Family Medicine and Preventive Medicine 5Department of Medical Sciences, Uppsala University, Uppsala, Sweden | ||||
Ann Rheum Dis |
||||
, Oral presentation | ||||
, Nordic, Sweden | ||||
Abstract: http://ard.bmj.com/content/74/Suppl_2/64.2 | ||||
Condition | Year | Language | Analysis type | |
, Rheumatology | 2015 | English | , Real World Evidence | |
Recurrence/progression and surgery of malignant melanoma in a retrospective Swedish cohort | ||||
Hansson J.*, Rockberg J., Taylor A., Jörgensen L., Linder R., Ragnhammar P., Amelio J | ||||
European Association of Dermato Oncology (EADO) Congress |
||||
, Abstract | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2015 | English | , Real World Evidence | |
Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study | ||||
Grundvold I1, Bodegard J2, Nilsson PM3, Svennblad B4, Johansson G5, Östgren CJ6, Sundström J7,8. | ||||
1Department of Cardiology, Oslo University Hospital, Ullevaal, PB 4956, Nydalen, 0424, Oslo, Norway. uxirgr@ous-hf.no. 2AstraZeneca Nordic, Södertälje, Sweden. Johan.Bodegard@astrazeneca.com. 3Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden. peter.nilsson@med.lu.se. 4Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. bodil.svennblad@ucr.uu.se. 5Department of Public health and Caring Science, Uppsala University, Uppsala, Sweden. gunnar.johansson@pubcare.uu.se. 6Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. carl.johan.ostgren@liu.se. 7Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. johan.sundstrom@medsci.uu.se. 8Department of Medical Sciences, Uppsala University, Uppsala, Sweden. johan.sundstrom@medsci.uu.se. | ||||
Cardiovasc Diabetol |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299152/ | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes | 2015 | English | , Real World Evidence | |
Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting | ||||
Sabale U1, Bodegård J2, Sundström J3, Östgren CJ4, Nilsson P5, Johansson G3, Svennblad B3, Henriksson M2. | ||||
1AstraZeneca Nordic-Baltic, Södertälje, Sweden. Electronic address: ugne.sabale@astrazeneca.com. 2AstraZeneca Nordic-Baltic, Södertälje, Sweden. 3Uppsala University, Uppsala, Sweden. 4Linköping University, Linköping, Sweden. 5Lund University, Malmö, Sweden | ||||
Prim Care Diabetes |
||||
, Nordic, Sweden | ||||
Abstract: http://www.primary-care-diabetes.com/article/S1751-9918(15)00002-9/abstract | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2015 | English | , Cost of illness, Real World Evidence | |
Healthcare utilisation and costs following initiation of insulin treatment in type 2 diabetes: a longterm follow-up in clinical practice | ||||
A. Kalkan1, J. Bodegard1, J. Sundström2, B. Svennblad2, C. Östgren3, P.M. Nilsson4, G. Johansson2, M. Ekman1 | ||||
1 AstraZeneca, Södertälje, 2Uppsala University, 3Linköping University, 4Lund University, Malmö, Sweden. | ||||
European Association for the Study of Diabetes (EASD) Annual Meeting; 2015; Stockholm |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://www.easdvirtualmeeting.org/resources/healthcare-utilisation-and-costs-following-initiation-of-insulin-treatment-in-type-2-diabetes-a-long-term-follow-up-in-clinical-practice--2 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2015 | English | , Cost of illness, Real World Evidence | |
Weight change over time and its link to healthcare costs among newly-diagnosed type 2 diabetes patients in Sweden | ||||
U. Sabale1, J. Bodegard1, J. Sundström2, B. Svennblad2, C. Östgren3, P.M. Nilsson4, G. Johansson2, M.Ekman1 | ||||
1AstraZeneca, Södertälje, 2Uppsala University, Uppsala, 3Linköping University, Linköping, 4Lund University, Malmö, Sweden. | ||||
European Association for the Study of Diabetes (EASD) Annual Meeting; 2015; Stockholm. |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://staging.easdvirtualmeeting.org/resources/weight-change-over-time-and-its-link-to-healthcare-costs-among-newly-diagnosed-type-2-diabetes-patients-in-sweden--2 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2015 | English | , Real World Evidence | |
Bladder Cancer Risk in Relation to Exposure to Pioglitazone among Patients with T2DM in the Pan European Multi-Database Bladder Cancer Risk Characterisation Study | ||||
Korhonen P, Haukka J, Tayler M, Haddad PM, Patel MX, Tiihonen J | ||||
EPID Research Ltd, Espoo, Finland | ||||
American Diabetes Association's 75th Scientific Session, Boston, USA, 5-9 June, 2015 |
||||
, Finland, Netherlands, Sweden, UK | ||||
Abstract: https://ada.scientificposters.com/epsAbstractADA.cfm?id=1 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2015 | English | , Population Based Study, Retrospective database analysis | |
Children's medication in the Nordic countries - Survey on national administrative register data | ||||
Långström D, Iso-Mustajärvi I, Sandler N, Prami T | ||||
Pharmaceutical Sciences Laboratory, Åbo Akademi University, Turku, Finland | ||||
Value in Health November 2015; 18 (7):A745–A746 |
||||
, Poster | ||||
, Finland, Sweden | ||||
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(15)04957-8/fulltext | ||||
Condition | Year | Language | Analysis type | |
, Pediatrics | 2015 | English | , Population Based Study, Retrospective database analysis | |
Population-based study of giant cell tumour of the bone in Sweden | ||||
Amelio J1, Sandberg J2, Hernandez RK4, Sobocki P2,Stryker S4, Engellau J3, Bach BA4, Liede A4 | ||||
1Center For Oberservational Research, Amgen Ltd., UB8 1DH - Uxbridge/UK 2., IMS Health, 113 46 - Stockholm/SE 3Center For Oberservational Research, Amgen Inc., Thousand Oaks/US 4Department Of oncology, Lund University Hospital, 221 00 - Lund/SE | ||||
ESMO 2014 CTOS 19th Annual Meeting, October 15- 18, 2014 at the InterContinental Hotel in Berlin, Germany |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Abstract: http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Sarcoma/Population-based-study-of-giant-cell-tumour-of-the-bone-in-Sweden | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2014 | English | , Database Study | |
Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia - estimates from population-based register data in Sweden | ||||
Banefelt J1, Hallberg S1, Fox KM2, Mesterton J1, Paoli CJ3, Johansson G4, Levin L5, Sobocki P6, Gandra SR3 | ||||
1Quantify Research, Stockholm, Sweden, 2Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 3Amgen, Inc., Thousand Oaks, CA, USA, 4Uppsala University, Uppsala, Sweden, 5Linköping University, Linköping, Sweden, 6IMS Health, Stockholm, Sweden | ||||
ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, 8-12 November, 2014 |
||||
, Podium presentation | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Cost of illness | |
Burden of hyperlipidemia resulting from productivity loss - estimates from population-based register data in Sweden | ||||
Banefelt J1, Hallberg S1, Gandra SR2, Mesterton J1, Fox KM3, Paoli CJ2, Johansson G4, Levin L5, Sobocki P6 | ||||
Quantify Research, Stockholm, Sweden, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 4Uppsala University, Uppsala, Sweden, 5Linköping University, Linköping, Sweden, 6IMS Health, Stockholm, Sweden | ||||
ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, 8-12 November, 2014 |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Burden of illness | |
Healthcare costs associated with cardiovascular events in patients with hyperlipidemia - estimates from population-based register data in Sweden | ||||
Hallberg S1, Banefelt J1, Mesterton J1, Gandra SR2, Fox KM3, Johansson G4, Levin L5, Sobocki P6 | ||||
1Quantify Research, Stockholm, Sweden, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 4Uppsala University, Uppsala, Sweden, 5Linköping University, Linköping, Sweden, 6IMS Health, Stockholm, Sweden | ||||
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Population Based Study | |
Healthcare costs associated with cardiovascular events in patients with hyperlipidemia - estimates from population-based register data in Sweden | ||||
Hallberg S1, Banefelt J1, Mesterton J1, Gandra SR2, Fox KM3, Johansson G4, Levin L5, Sobocki P6 | ||||
1Quantify Research, Stockholm, Sweden, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 4Uppsala University, Uppsala, Sweden, 5Linköping University, Linköping, Sweden, 6IMS Health, Stockholm, Sweden | ||||
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Cost of illness, Population Based Study | |
LDL-C goal attainment in patients with hyperlipidemia - estimates from population-based register data in Sweden | ||||
Mesterton J1, Hallberg S1, Gandra SR2, Banefelt J1, Fox KM3, Johansson G4, Levin L5, Sobocki P6 | ||||
Quantify Research, Stockholm, Sweden, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 4Uppsala University, Uppsala, Sweden, 5Linköping University, Linköping, Sweden, 6IMS Health, Stockholm, Sweden | ||||
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Population Based Study | |
Treatment patterns in hyperlipidemia patients with new cardiovascular events - estimates from population-based register data in Sweden | ||||
Hallberg S1, Banefelt J1, Fox KM2, Mesterton J1, Johansson G3, Levin L4, Sobocki P5, Gandra SR6 | ||||
1Quantify Research, Stockholm, Sweden, 2Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 3Uppsala University, Uppsala, Sweden, 4Linköping University, Linköping, Sweden, 5IMS Health, Stockholm, Sweden, 6Amgen, Inc., Thousand Oaks, CA, USA | ||||
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Database Study | |
Retrospective database study on healthcare resource utilization of patients initiating long-acting olanzapine in Sweden | ||||
Tockhorn A1, Johansson S2, Borgeke H3 | ||||
1Eli Lilly UK, Windlesham, Surrey, UK, 2IMS Health Sweden, 113 46 Stockholm, Sweden, 3Eli Lilly and Company, Stockholm, Sweden | ||||
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2014 | English | , Retrospective database analysis | |
Cost-effectiveness of ipilimumab in previously untreated patients for advanced melanoma in Sweden | ||||
Barzey V1, Asukai Y1, Gueron B2, Holmberg C3, Kotapati S4 | ||||
1IMS Health, London, UK, 2Bristol-Myers Squibb, Rueil Malmasion, France, 3Bristol-Myers Squibb, Bromma, Sweden, 4Bristol-Myers Squibb Pharmaceuticals, Wallingford, CT, USA | ||||
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2014 | English | , Cost effectiveness | |
Transforming oncology outcomes research through data linkage in Sweden: A unique real-world lens on the entire patient journey | ||||
Sobocki P | ||||
IMS Health, Stockholm, Sweden | ||||
AccessPoint, 2014, May; 4(8): 21-25 |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://issuu.com/ims_heor_publications/docs/ims_rwe_accesspoint_8_-_250514f_iss | ||||
Condition | Year | Language | Analysis type | |
, Methodology, Oncology | 2014 | English | , Real World Evidence | |
A retrospective study of mortality in risk patients with high dose statin usage and no statin usage | ||||
Rockberg J1, Jørgensen L1, Taylor B2, Kilpatrick RD2, Sobocki P1 | ||||
1Pygargus/IMS Health, Stockholm, Sweden, 2Amgen Inc, Thousand Oaks, CA, USA | ||||
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Retrospective database analysis | |
Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. | ||||
Hoogendoorn M1, Feenstra TL2, Asukai Y3, Borg S4, Hansen RN5, Jansson SA6, Samyshkin Y3, Wacker M7, Briggs AH8, Lloyd A3, Sullivan SD5, Rutten-van Mölken1 MP. | ||||
1Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands. 2Department for Prevention and Health Services Research, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Department of Epidemiology, University Medical Centre Groningen, The Netherlands.3IMS Health, Health Economics and Outcomes Research, Real-World Evidence Solutions, London, UK 4The Swedish Institute for Health Economics, Lund, Sweden 5Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA 6The OLIN Studies, Luleå, Sweden 7Helmholtz Zentrum München, Institute of Health Economics and Health Care Management, Comprehensive Pneumology Center Munich, Neuherberg, Germany. 8Institute of Health & Wellbeing, University of Glasgow, UK. | ||||
Value Health. 2014 Jul;17(5):525-36. |
||||
, Article | ||||
, Germany, Netherlands, Sweden, UK, USA | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2014 | English | , Cost effectiveness | |
Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden | ||||
Banefelt J1, Liede A2, Mesterton J3, Stålhammar J4, Hernandez RK5, Sobocki P6, Persson BE7. | ||||
1Quantify Research, Hantverkargatan 8, 112 21 Stockholm, Sweden. 2Amgen Inc., Center for Observational Research, South San Francisco, CA, United States. 3Quantify Research, Hantverkargatan 8, 112 21 Stockholm, Sweden; Institute of Environmental Medicine, Karolinska Institute, 171 77 Stockholm, Sweden. 4Department of Public Health and Caring Sciences, Uppsala University, 751 22 Uppsala, Sweden. 5Amgen Inc., Center for Observational Research, One Amgen Center Drive 24-2-A, Thousand Oaks, CA 91320, United States. 6IMS Health/Pygargus, Sveavägen 155, 113 46 Stockholm, Sweden; LIME/Medical Management Centre, Karolinska Institute, 171 77 Stockholm, Sweden. 7Uppsala University, 751 05 Uppsala, Sweden. Electronic address: Bo-Eric.Persson@ferring.com. | ||||
Cancer Epidemiol |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://www.cancerepidemiology.net/article/S1877-7821(14)00089-7/abstract | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2014 | English | , Real World Evidence | |
The burden of preserved ejection fraction heart failure in a real-world Swedish patient Population | ||||
Stålhammar Ja, Stern Lb, Linder Rc, Sherman Sb, Parikh Rb, Ariely Rd, Deschaseaux Ce, Wikström Ga. | ||||
a Uppsala University Uppsala Sweden b LA-SER Analytica New York, NY USA c Pygargus AB Stockholm Sweden d GlaxoSmithKline, Inc. Clifton, NJ USA e Novartis, Inc. Basel Switzerland | ||||
J Med Econ |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.tandfonline.com/doi/full/10.3111/13696998.2013.848808 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Real World Evidence | |
Burden Of Hyperlipidemia Resulting From Productivity Loss - Estimates From Population-Based Register Data In Sweden | ||||
Banefelt J.1, Hallberg S.1, Gandra S.R.2, Mesterton J.1, Fox K.M.3, Paoli C.J.2, Johansson G.4, Levin L.Å.5, Sobocki P.6 | ||||
1Quantify Research, Stockholm, Sweden, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 4Uppsala University, Uppsala, Sweden, 5Linköping University, Linköping, Sweden, 6IMS Health, Stockholm, Sweden | ||||
Value in Health |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(14)03384-1/abstract | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Real World Evidence | |
TREATMENT PATTERNS IN HYPERLIPIDEMIA PATIENTS WITH NEW CARDIOVASCULAR EVENTS - ESTIMATES FROM POPULATION-BASED REGISTER DATA IN SWEDEN | ||||
Hallberg S1, Banefelt J1, Fox KM2, Mesterton J1, Johansson G3, Levin L4, Sobocki P5, Gandra SR6 | ||||
1Quantify Research, Stockholm, Sweden, 2Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 3Uppsala University, Uppsala, Sweden, 4Linköping University, Linköping, Sweden, 5IMS Health, Stockholm, Sweden, 6Amgen, Inc., Thousand Oaks, CA, USA | ||||
ISPOR 17th Annual European Congress Amsterdam, The Netherlands November, 2014 |
||||
, Abstract, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/research_study_digest/details.asp | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Real World Evidence | |
HEALTH CARE COSTS ASSOCIATED WITH CARDIOVASCULAR EVENTS IN PATIENTS WITH HYPERLIPIDEMIA - ESTIMATES FROM POPULATION-BASED REGISTER DATA IN SWEDEN | ||||
Hallberg S1, Banefelt J1, Mesterton J1, Gandra SR2, Fox KM3, Johansson G4, Levin L5, Sobocki P6 | ||||
1Quantify Research, Stockholm, Sweden, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 4Uppsala University, Uppsala, Sweden, 5Linköping University, Linköping, Sweden, 6IMS Health, Stockholm, Sweden | ||||
ISPOR 17th Annual European Congress Amsterdam, The Netherlands November, 2014 |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://www.ispor.org/research_study_digest/details.asp | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Real World Evidence | |
A RETROSPECTIVE STUDY OF MORTALITY IN RISK PATIENTS WITH HIGH DOSE STATIN USAGE AND NO STATIN USAGE | ||||
Rockberg J1, Jørgensen L1, Taylor B2, Kilpatrick RD2, Sobocki P1 | ||||
1Pygargus/IMS Health, Stockholm, Sweden, 2Amgen Inc, Thousand Oaks, CA, USA | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/research_study_digest/details.asp | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Real World Evidence | |
Population-based study of giant cell tumour of the bone in Sweden. | ||||
Amelio J.1, Sandberg J.2, Hernandez R.H.3, Sobocki P.4, Stryker S.5, Engellau J.6, Bach B.A.3, Liede A.5 | ||||
1Amgen Ltd. Uxbridge, UK 2Pygargus/IMS Health, Stockholm, Sweden 3Amgen Inc. Thousand Oaks, CA, USA 4Pygargus/IMS Health, Stockholm, Sweden; Karolinska Institutet, Stockholm, Sweden 5Amgen Inc. South San Francisco, CA, USA. 6Lund University, Lund, Sweden. | ||||
The Connective Tissue Oncology Society (CTOS) Annual Meeting 2014 October 15–18, Berlin Germany |
||||
, Oral presentation | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2014 | English | , Real World Evidence | |
Population-based study of giant cell tumour of the bone in Sweden | ||||
J. Amelio1, J. Sandberg2, R.K. Hernandez3, P. Sobocki2, S. Stryker3, J. Engellau4, B. Bach3, A. Liede3 | ||||
1Center For Oberservational Research, Amgen Ltd., UB8 1DH - Uxbridge/UK 2., IMS Health, 113 46 - Stockholm/SE 3Center For Oberservational Research, Amgen Inc., Thousand Oaks/US 4Department Of Oncology, Lund University Hospital, 221 00 - Lund/SE | ||||
European Society for Medical Oncology Meeting 2014, 29 Sept 2014, Madrid Spain |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Sarcoma/Population-based-study-of-giant-cell-tumour-of-the-bone-in-Sweden | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2014 | English | , Real World Evidence | |
Trends in giant cell tumour of the bone and osteosarcoma incidence in the Sweden (1958-2011. | ||||
A. Liede1, J. Sandberg2, J. Amelio3, R.K. Hernandez4, P. Sobocki2, H.C..F. Bauer5, B. Bach6, J. Engellau7 | ||||
1Center For Observational Research, Amgen Inc., 94080 - South San Francisco/US 2., IMS Health, 113 46 - Stockholm/SE 3Center For Oberservational Research, Amgen Ltd., UB8 1DH - Uxbridge/UK 4Center For Observational Research, Amgen Inc., 91320 - Thousand Oaks/US 5Molecular Medicine And Surgery, Karolinska Institute, Stockholm/SE 6Clinical Development, Amgen Inc., Thousand Oaks/US 7Department Of Oncology, Lund University Hospital, 221 00 - Lund/SE | ||||
European Society for Medical Oncology (ESMO) Meeting 2014, Madrid Spain, 29 September |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Sarcoma/Trends-in-Giant-Cell-Tumour-of-the-Bone-and-Osteosarcoma-Incidence-in-the-Sweden-1958-2011 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2014 | English | , Real World Evidence | |
Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study. | ||||
Lisspers K1, Johansson G2, Jansson C3, Larsson K4, Stratelis G5, Hedegaard M6, Ställberg B2. | ||||
1Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, BMC, Box 564, SE-751 22 Uppsala, Sweden. Electronic address: karin.lisspers@ltdalarna.se. 2Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, BMC, Box 564, SE-751 22 Uppsala, Sweden. 3Department of Medical Sciences, Respiratory Medicine and Allergology, Uppsala University, Akademiska sjukhuset, SE-751 85 Uppsala, Sweden. 4Unit of Lung and Allergy Research, National Institute of Environmental Medicine, Karolinska Institutet, Box 210, SE-171 77 Stockholm, Sweden. 5AstraZeneca Nordic-Baltic, SE-151 85 Södertälje, Sweden. 6Formerly AstraZeneca Nordic-Baltic, DK-2300 Copenhagen S, Denmark. | ||||
Respir Med |
||||
, Sweden | ||||
Abstract: http://www.resmedjournal.com/article/S0954-6111(14)00229-7/abstract | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2014 | English | , Real World Evidence | |
Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS) | ||||
Ställberg B1, Janson C, Johansson G, Larsson K, Stratelis G, Telg G, Lisspers KH. | ||||
1Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden | ||||
Prim Care Respir J |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://www.nature.com/articles/pcrj2013106 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2014 | English | , Epidemiological study, Real World Evidence | |
Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD | ||||
Hedegaard M1, Janson C2, Lisspers K2, Ställberg B2, Johansson G2, Jørgensen L3, Larsson K4 | ||||
1 AstraZeneca, Copenhagen S, Denmark, 2 Uppsala University, Uppsala, Sweden, 3 AstraZeneca, Södertälje, Sweden, 4 Karolinska Institutet, Stockholm, Sweden | ||||
Eur Respir J Value in Health |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(13)01264-3/abstract | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2014 | English | , Cost effectiveness, Real World Evidence | |
Pneumonia in COPD patients treated with fixed ICS/LABA combinations | ||||
Christer Janson1, Kjell Larsson2, Karin Lisspers3, Björn Ställberg3, Georgios Stratelis4, Gunilla Telg4, Leif Jörgensen4 and Gunnar Johansson5 | ||||
1Department of Medical Sciences, Respiratory Medicine, Uppsala University, Uppsala, Sweden 2Unit of Lung and Allergy Research, National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden 3Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology, Uppsala University, Uppsala, Sweden 4Medical, AstraZeneca Nordic, Södertälje, Sweden 5Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden | ||||
Eur Respir J |
||||
, Sweden | ||||
Abstract: http://erj.ersjournals.com/content/40/Suppl_56/P2897 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2014 | English | , Real World Evidence | |
Patients with COPD who Initiate Roflumilast in Sweden | ||||
Khalid J.M.1, Mushnikov V.2, Vattulainen P.2, Johansson G.3, Korhonen P. 2, Hoti F.2 | ||||
1Takeda Development Centre Europe, Ltd., London, UK, 2EPID Research, Espoo, Finland, 3Uppsala University, Uppsala, Sweden | ||||
ISPOR 17th Annual European Congress, nov 8-12, 2014, Amsterdam, The Netherlands. |
||||
, Nordic, Sweden | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(14)03952-7/abstract | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2014 | English | , Real World Evidence | |
Costs and effects of structured COPD care - An observational, matched-cohort study | ||||
Karin Lisspers1, Gunnar Johansson1, Christer Jansson2, Georgios Stratelis3, Leif Jörgensen3, Kjell Larsson4, Morten Hedegaard5 and Björn Ställberg1 | ||||
1Department of Public Health and Caring Services, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden 2Department of Medical Sciences, Respiratory Medicine, Uppsala University, Uppsala, Sweden 3R&D, Astrazeneca, Södertälje, Sweden 4Unit of Lung and Allergy Research, National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden 5Global Commercial, Astrazeneca, Copenhagen, Denmark | ||||
Eur Respir J |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://erj.ersjournals.com/content/42/Suppl_57/P2418.article-info | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2014 | English | , Real World Evidence | |
Association of Changes In Body Weight With Health Care Costs Among Patients With Newly-Diagnosed Type-2 Diabetes In Sweden | ||||
U. Sabale1, J. Bodegård1, J. Sundström2, B. Svennblad3, C.J. Östgren4, P. Nilsson5, G. Johansson3, M. Henriksson1 | ||||
1 AstraZeneca Nordic-Baltic, Södertälje, Sweden, 2 Uppsala University, Uppsala, Australia, 3 Uppsala University, Uppsala, Sweden, 4 Linköping University, Linköping, Sweden, 5 Lund University, Malmö, Sweden | ||||
Value in Health |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://www.sciencedirect.com/science/article/pii/S109830151402590X | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2014 | English | , Real World Evidence | |
Population-based study of Giant Cell Tumor of the bone in Sweden | ||||
Amelio J, Sandberg J, Hernandez R, Sobocki P, Stryker S, Engellau J, Bach B, Liede A | ||||
Center for Oberservational Research, Amgen Ltd., Uxbridge, UK|IMS Health, Stockholm Sweden | ||||
Annals of Oncology (2014) 25(suppl 4):iv509-iv510 |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Abstract: https://academic.oup.com/annonc/article/25/suppl_4/iv509/2242151 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2014 | English | , Epidemiological study, Population Based Study, Retrospective database analysis | |
Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries. | ||||
Divino V., DeKoven M., Hallinan S., Varol N., Wirta SB., Lee WC., Reaney M. | ||||
Lilly. IMS authors: Divino V, DeKoven M | ||||
Diabetes Ther. |
||||
, Article | ||||
, Belgium, France, Germany, Netherlands, Sweden, UK | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/25366334 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2014 | English | , Retrospective database analysis | |
Work Productivity Loss and Indirect Costs Associated with New Cardiovascular Events in High-Risk Patients with Hyperlipidemia - Estimates from Population-Based Register Data in Sweden | ||||
Banefelt J, Hallberg S, Fox KM, Mesterton J, Paoli CJ, Johansson G, Levin LA, Sobocki P, Gandra SR | ||||
Quantify Research, Stockholm, Sweden|IMS Health, Stockholm, Sweden | ||||
Value in health:The journal of the International Society for Pharmacoeconomics and Outcomes Research (2014);17(7):A327-328 |
||||
, Oral presentation | ||||
, Nordic, Sweden | ||||
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(14)02526-1/fulltext | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2014 | English | , Cost analysis, Cost of illness, Population Based Study, Retrospective database analysis | |
Exacerbations and healthcare resource utilization among COPD patients in Sweden | ||||
Hoti F, Mushnikov V, Vattulainen P, Johansson G, Khalid JM, Korhonen P | ||||
EPID Research, Espoo, Finland | ||||
ERS International Congress 2014, Munich, Germany, 6-10 Sep, 2014 |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Abstract: http://epidresearch.com/wp-content/uploads/2016/11/EPID-Research-poster-ERS-2014.pdf | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2014 | English | , Burden of illness, Clinical setting: hospital, clinical setting: Secondary care, Population Based Study, Retrospective database analysis | |
Patients With COPD who Initiate Roflumilast in Sweden | ||||
Khalid JM, Mushnikov V, Vattulainen P, Johansson G, Korhonen P, Hoti F | ||||
Takeda Development Centre Europe, Ltd., London, UK. | ||||
Value Health (2014);17(7): A590 |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Abstract: https://ac.els-cdn.com/S1098301514039527/1-s2.0-S1098301514039527-main.pdf?_tid=8ac08c65-061d-4f1f-9dd7-ab7e57390da9&acdnat=1537855638_d812a58ce69b69727a8d22b21f1ed84a | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2014 | English | , Observational study, Population Based Study | |
ASSOCIATION OF CHANGES IN BODY WEIGHT WITH HEALTH CARE COSTS AMONG PATIENTS WITH NEWLY-DIAGNOSED TYPE-2 DIABETES IN SWEDEN | ||||
Sabale U, Bodegård J, Sundström J, Svennblad B, Östgren CJ, Nilsson P, Johansson G, Henriksson M | ||||
AstraZeneca Nordic-Baltic, Södertälje, Sweden | ||||
Value in Health (2014);17(7): A338 |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(14)02590-X/fulltext | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2014 | English | , Cost analysis, Population Based Study, Retrospective database analysis | |
A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden | ||||
Fredrikson S1, McLeod E2, Henry N2, Pitcher A2, Lowin J2, Cuche M3, Fajutrao L4, Perard R5, Bates D6, Chan A7 | ||||
1 Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden 2 IMS Health, London, UK 3 Merck Serono S.A., Geneva, Switzerland 4 Merck AB, Solna, Sweden 5 Merck Serono Ltd, Middlesex, UK 6 Newcastle University, Newcastle upon Tyne, UK 7 Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany | ||||
J Med Econ. 2013;16(6):756-62. |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://informahealthcare.com/doi/abs/10.3111/13696998.2013.792824?journalCode=jme | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2013 | English | , Cost effectiveness | |
Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients. | ||||
Sundström J, Sheikhi R, Ostgren CJ, Svennblad B, Bodegård J, Nilsson PM, Johansson G. | ||||
IMS Health (Formally Pygargus) | ||||
J Hypertens. 2013 Aug;31(8):1603-10 |
||||
, Abstract, Article | ||||
, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23625112 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes | 2013 | English | , Retrospective cohort analysis | |
Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care. | ||||
Östgren CJ, Sundström J, Svennblad B, Lohm L, Nilsson PM, Johansson G. | ||||
IMS Health, Stockholm, Sweden (Formally Pygargus) | ||||
Diabet Med. 2013 May;30(5):e170-7 |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23350893 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes | 2013 | English | , Retrospective cohort analysis | |
Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. | ||||
Larsson K, Janson C, Lisspers K, Jørgensen L, Stratelis G, Telg G, Ställberg B, Johansson G. | ||||
IMS Health, Stockholm, Sweden (Formally Pygargus) | ||||
J Intern Med. 2013 Jun;273(6):584-94 |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23495860 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2013 | English | , Retrospective cohort analysis | |
Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS) | ||||
Christer Janson1, Kjell Larsson2,Karin H Lisspers3, Björn Ställberg3, Georgios Stratelis4, Helena Goike4, Leif Jörgensen4, Gunnar Johansson5 | ||||
1Department of Medical Sciences, Respiratory Medicine, Uppsala University, Uppsala, Sweden, 2Unit of Lung and Allergy Research, National Institute of Environmental Medicine, Karolinska Institute, Stockholm, 3Department of Public Health and Caring Science, Family Medicine and Clinical Epidemiology, Uppsala University, Uppsala, Sweden, 4AstraZeneca Nordic, Södertälje, Sweden, 5IMS Health, Stockholm (Formally Pygargus) | ||||
BMJ 2013;346:f3306. Doi: 10.1136/bmj.f3306 |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.bmj.com/content/346/bmj.f3306 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2013 | English | , Observational study, Retrospective cohort analysis | |
Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8,486 primary care patients | ||||
Bodegard J, Sundström J, Svennblad B, Östgren CJ, Nilsson PM, Johansson G | ||||
IMS Health, Stockholm, Sweden (Formally Pygargus) | ||||
Diabetes Metab. 2013 Sep;39(4):306-13 |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23871502 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes | 2013 | English | , Retrospective cohort analysis | |
COPD Exacerbations And Pneumonia On Triple Therapy (Fixed ICS/LABA Combinations And Tiotropium). Does The Choice Of ICS/LABA Matter? | ||||
Gunnar Johansson , MD, PhD 1 , Christer Janson , MD, PhD 1 , Björn Stallberg , MD, PhS 1 , Karin Lisspers , MD, PhD 1 , Georgios Stratelis , MD, PhD 2 , Leif Jorgensen , MSc 2 , Kjell Larsson , MD, PhD 3 | ||||
1 Uppsala University, Uppsala, Sweden 2 AstraZeneca Nordic, Södertälje, Sweden 3 Karolinska Institutet, Stockholm, Sweden | ||||
American Thoracic Society 2013 International Conference, May 17-22, 2013 - Philadelphia Pennsylvania |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A2442 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2013 | English | , Real World Evidence | |
Pneumonia Events And Choice Of Fixed ICS/LABA Combination In COPD. Influence Of ICS Dose And Burden Of Disease At Treatment Start | ||||
Gunnar Johansson , MD, PhD 1 , Kjell Larsson , MD, PhD 2 , Karin Lisspers , MD, PhD 1 , Björn Stallberg , MD, PhD 1 , Leif Jorgensen , MSc 3 , Georgios Stratelis , MD, PhD 3 , Christer Janson , MD, PhD 1 | ||||
1 Uppsala University, Uppsala, Sweden 2 Karolinska Institutet, Stockholm, Sweden 3 AstraZeneca Nordic, Södertälje, Sweden | ||||
American Thoracic Society 2013 International Conference, May 17-22, 2013 - Philadelphia Pennsylvania |
||||
, Sweden | ||||
Abstract: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A2443 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2013 | English | , Real World Evidence | |
Are Patients with Central and Branch Retinal Vein Occlusion at Increased Risk of Cardiovascular Disease? | ||||
Bruce Wirta S1, Löfroth E1, Tambour M2, Myrén KJ1 | ||||
1: IMS Health, Sveavägen 155, 113 46 Stockholm, Sweden 2: Novartis Sverige AB, Kemistvägen 1B, PO Box 1150, S-183 11 Täby, Sweden | ||||
28th International Conference on Pharmacoepidemiology & Theraputic Risk Management, Barcelona, Spain, 2012 |
||||
, Presentation | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Ophthalmology | 2012 | English | , Retrospective database analysis | |
The Potential Cost-Effectiveness of Glycopyrrolate, a Novel LAMA | ||||
Baldwin M1, Thuresson PO2, Asukai Y3 | ||||
1Novartis, UK; 2IMS Health, Switzerland; 3IMS Health, UK | ||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2012 | English | , Cost effectiveness | |
Length of stay and costs for patients with recurrent Clostridium Difficile infections in Sweden | ||||
Norén T1, Bruce S2, Fagerlund K3, Nordling S3 | ||||
1Department of Infectious Diseases, Örebro, Sweden, 2IMS Health, Stockholm, Sweden, 3Astellas Pharma Nordic, Kastrup, Denmark | ||||
ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Berlin1112/Posters2.aspx | ||||
Condition | Year | Language | Analysis type | |
, Infectious disease | 2012 | English | , Cost analysis | |
Weight gain within the first year after new onset diabetes is associated with risk of cardiovascular mortality: a cohort of 8,326 primary care patients. | ||||
Bodegard J1, Sundström J2, Svennblad B3, Östgren C4, Nilsson PM5, Johansson G2 | ||||
1 Medical Department, AstraZeneca, Oslo, Norway, 2 Uppsala University, Sweden, 3 Uppsala Clinical Research Center, Sweden, 4 Linköping University, Sweden, 5Lund University, Sweden | ||||
48th EASD Annual Meeting of the European Association for the Study of Diabetes; 2012; Berlin, Germany |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://www.easdvirtualmeeting.org/resources/weight-gain-within-the-first-year-after-new-onset-diabetes-is-associated-with-risk-of-cardiovascular-mortality-a-cohort-of-8-326-primary-care-patients | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2012 | English | , Real World Evidence | |
COPD in primary care in Sweden - An 11 years epidemiological register study | ||||
Karin Lisspers1, Kjell Larsson2, Björn Ställberg1, Christer Janson3, Gunilla Telg4, Leif Jörgensen4, Georgios Stratelis4 and Gunnar Johansson1 | ||||
1Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology, Uppsala University, Uppsala, Sweden 2Unit of Lung and Allergy Research, National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden 3Department of Medical Sciences, Respiratory Medicine, Uppsala University, Uppsala, Sweden 4Medical, AstraZeneca Nordic, Södertälje, Sweden | ||||
Eur Respir J |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://erj.ersjournals.com/content/40/Suppl_56/4339.article-info | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2012 | English | , Real World Evidence | |
Jämförelse av behandling med kombinationsläkemedel (ICS/LABA) vid KOL – en populationsbaserad och matchad observationsstudie. | ||||
Janson C, Lisspers K, Ställberg B, et al. | ||||
Uppsala University | ||||
Medicinska Riksstämman 2012, Sverige |
||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2012 | Swedish | , Real World Evidence | |
Automated data extraction—A feasible way to construct patient registers of primary care utilization | ||||
Martinell M, Stalhammar J, Hallqvist J | ||||
Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden | ||||
Upsala Journal of Medical Sciences (2012);117(1):52-56 |
||||
, Article | ||||
, Sweden | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282243/ | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2012 | English | , Clinical setting: Primary care, Real World Evidence | |
Effectiveness of fixed ICS/LABA combinations in COPD - A population based register linkage study | ||||
Stallberg B, Janson C,Lisspers K,Johansson G,Jörgensen L,Stratelis G,Telg G,Larsson K | ||||
Dep. of Public Health and Caring Science, Family Medicine and Clinical Epidemiology, Uppsala University, Uppsala, Sweden | ||||
European Respiratory Journal (2012);40(Suppl 56) |
||||
, Abstract | ||||
, Sweden | ||||
Abstract: http://erj.ersjournals.com/content/40/Suppl_56/P740 | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2012 | English | , Population Based Study, Retrospective database analysis | |
Duration of time off paid employment associated with diabetes-related complications | ||||
Beaudet A1, Myrén K-J2, Grant D3, Lloyd A3 | ||||
1 IMS Health, Basel, Switzerland, 2 IMS Health, Stockholm, Sweden, 3 IMS, Health, London, UK | ||||
47th EASD Annual Meeting, Lisbon, Portugal, 12 - 16 September 2011 |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2011 | English | , Observational study | |
Treatment of urinary tract infections is common amongst Swedish patients in need of chronic catheterisation | ||||
Bruce S1, Löfroth E1, Knutsson B2, Börstell T2, Myrén KJ1 | ||||
1 IMS Consulting Group, Stockholm, Sweden. 2 AstraTech, Mölndal, Sweden. | ||||
ISPOR 14th Annual European Congress, 2010, 5-8 November, Madrid, Spain |
||||
, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Spain1111/Posters1.aspx | ||||
Condition | Year | Language | Analysis type | |
, Infectious disease, Urology | 2011 | English | , Burden of illness, Epidemiological study, Retrospective database analysis | |
Resource utilisation related to catheter-associated urinary tract infections in Swedish spinal injury patients | ||||
Bruce S1, Löfroth E1, Knutsson B2, Börstell T2, Myrén KJ1. | ||||
1 IMS Consulting Group, Stockholm, Sweden. 2 AstraTech, Mölndal, Sweden. | ||||
ISPOR 14th Annual European Congress, 2010, 5-8 November, Madrid, Spain |
||||
, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Spain1111/Posters1.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Infectious disease, Urology | 2011 | English | , Burden of illness, Cost analysis, Epidemiological study, Retrospective database analysis | |
Resource utilisation related to urinary tract infections in Swedish self-catheterisation patients | ||||
Löfroth E1, Bruce S1, Knutsson B2, Börstell T2, Myrén KJ1. | ||||
1 IMS Consulting Group, Stockholm, Sweden. 2 AstraTech, Mölndal, Sweden. | ||||
ISPOR 14th Annual European Congress, 2010, 5-8 November, Madrid, Spain |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Infectious disease, Urology | 2011 | English | , Burden of illness, Cost analysis, Epidemiological study, Retrospective database analysis | |
Drug utilisation adaptions in Sweden after the Effexor patent expiry | ||||
Bruce S, Hjelmgren J, Löfroth E, Myrén KJ. | ||||
IMS Consulting Group, Stockholm, Sweden. | ||||
ISPOR 14th Annual European Congress, 2010, 5-8 November, Madrid, Spain |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Spain1111/Posters1.aspx | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice, Health policy, Mental health | 2011 | English | , Retrospective database analysis | |
Real world add-on and switch patterns for platelet and aggregation inhibitors | ||||
Löfroth E, Bruce S, Myrén KJ. | ||||
IMS Consulting Group, Stockholm, Sweden. | ||||
ISPOR 14th Annual European Congress, 2010, 5-8 November, Madrid, Spain |
||||
, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Spain1111/Posters2.aspx | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Clinical practice, Vascular disease | 2011 | English | , Epidemiological study, Retrospective database analysis | |
Health-care costs of losartan and candesartan in the primary treatment of hypertension | ||||
Henriksson M, Russell D, Bodegard J, Kjeldsen S, Hasvold P, Stålhammar J, Levin LÅ. | ||||
IMS Health, Stockholm. (Formally Pygargus) | ||||
J Hum Hypertens. 2011 Feb;25(2):130-6. doi: 10.1038/jhh.2010.36. Epub 2010 Apr 8. |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20376078 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2011 | English | , Cost analysis | |
Healthcare encounters among heart failure patients with preserved ejection fraction (HF-PEF) and reduced ejection fraction (HF-REF) in Sweden | ||||
Wikstrom G1, Stalhammar J2, Ariely R3, Linder R4, Ogbonnaya A5, Stern L5 | ||||
1Uppsala University, Department of Medical Sciences, Cardiology, Uppsala, Sweden, 2Uppsala University, Department of Public Health and Caring Sciences, Uppsala,Sweden, 3 Novartis Pharmaceuticals Corporation, East Hanover, USA, 4IMS Health (Formally Pygargus AB), Stockholm, Sweden, 5Analytica International, New York, USA | ||||
European Heart Failure Congress, Gothenbourg, May 21-24, 2011 |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://spo.escardio.org/SessionDetails.aspx?eevtid=46&sessId=7804&subSessId=1013&searchQuery=&presId=54107&doc=Abstract | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2011 | English | , Cost utility, Retrospective database analysis | |
Mortality and admission rates among heart failure patients with preserved ejection fraction (HF-PEF) and reduced ejection fraction (HF-REF) in Sweden | ||||
Wikstrom G1, Stalhammar J2, Ariely R3, Linder R4, Ogbonnaya A5, Stern L5 | ||||
1Uppsala University, Department of Medical Sciences, Cardiology, Uppsala, Sweden, 2Uppsala University, Department of Public Health and Caring Sciences, Uppsala,Sweden, 3Novartis Pharmaceuticals Corporation,East Hanover,USA, 4IMS Health,(Formally Pygargus AB)Stockholm, Sweden, 5Analytica International, New York, USA | ||||
European Heart Failure Congress, Gothenbourg, May 21-24, 2011 |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: http://spo.escardio.org/Abstract.aspx?eevtid=46&fp=P1289 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2011 | English | , Retrospective cohort analysis, Retrospective database analysis | |
Systolic and diastolic blood pressure levels associated with lowest risk in type 2 diabetes: a cohort study of 37,798 primary care patients | ||||
Sundström1 J2, Östgren CJ3, Svennblad B2, Sheikhi R1, Bodegård J4, Nilsson PM5, Johansson G6 | ||||
1Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden, 3Department of Medical and Health Sciences, Linköping University, Linköping, Sweden, 4AstraZeneca Nordic, Södertälje, Sweden, 5Department of Clinical Sciences, Lund University, Lund, Sweden, 6Department of Public Health & Caring Sciences, Uppsala University, Uppsala, Sweden | ||||
47th EASD Annual Meeting, Lisbon, Portugal. Presentation 53, Tuesday, Sep 13, 2011. |
||||
, Presentation | ||||
, Sweden | ||||
Abstract: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=237d5d03-5ca2-4781-b2af-ae93644fb307&cKey=e87414dc-b005-45f9-a81e-84610372dcf1&mKey=%7bBAFB2746-B0DD-4110-8588-E385FAF957B7%7d | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes | 2011 | English | , Retrospective cohort analysis | |
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. | ||||
Jose´ R. Banegas 1,2*, Esther Lo´pez-Garcı´a 1,2, Jean Dallongeville3, Eliseo Guallar 4,5,6,7, Julian P. Halcox8, Claudio Borghi 9, Elvira L. Masso´-Gonza´lez 10, Francisco J. Jime´nez 11, Joep Perk12, Philippe Gabriel Steg13, Guy De Backer 14,and Fernando Rodrı´guez-Artalejo1,2 | ||||
1 Department of Preventive Medicine and Public Health, School of Medicine, Universidad Auto´noma de Madrid/IdiPAZ, Avda Arzobispo Morcillo, 2, 28029 Madrid, Spain; 2 CIBER of Epidemiology and Public Health, Madrid, Spain; 3 Inserm U 744, Institut Pasteur de Lille, 59019 Lille Cedex, France; 4 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 5 Department of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 6 Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 7 Department of Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Research (CNIC), Madrid 28029, Spain; 8 Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; 9 Department of Internal Medicine, Aging and Clinical Nephrology, University of Bologna, Bologna, Italy; 10Medical Department, AstraZeneca Farmace´utica Spain, S.A., 28003 Madrid, Spain; 11Medical Department, AstraZeneca Europe, 1935 Zaventem, Belgium; 12School of Health and Caring Sciences, Linnaeus University, 391 82 Kalmar, Sweden; 13INSERM U 698, Assistance Publique–Hoˆpitaux de Paris and Universite´ Paris-Diderot, Paris, France; and 14Department of Public Health, University of Gent, 9000 Gent, Belgium | ||||
Eur Heart J. 2011 Sep;32(17):2143-52 |
||||
, Article | ||||
, Austria, Belgium, France, Germany, Greece, Norway, Spain, Sweden, Switzerland, Turkey, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21471134 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2011 | English | , Observational study, Prospective study | |
Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. | ||||
Guallar E, Banegas JR, Blasco-Colmenares E, Jiménez FJ, Dallongeville J, Halcox JP, Borghi C, Massó-González EL, Tafalla M, Perk J, De Backer G, Steg PG, Rodríguez-Artalejo F. | ||||
BMC Public Health. 2011 Sep 18;11:704. doi: 10.1186/1471-2458-11-704. |
||||
, Article | ||||
, Austria, Belgium, France, Germany, Greece, Norway, Russian Federation, Spain, Sweden, Switzerland, Turkey, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21923932 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2011 | English | , Observational study, Prospective study | |
Association of HbA1c with the risk of cardiovascular events in patients with type 2 diabetes: a cohort study of 40, 204 patients in primary care. | ||||
Östgren C1, Sundstrom C2, Svennblad B3, Lohm L4, Nilsson P5, Johansson G2 | ||||
1 Linköping University, Linköping, Sweden 2 Uppsala University, Uppsala, Sweden 3 Uppsala Clinical Research Center, Uppsala, Sweden 4 AstraZeneca Nordic, Södertälje, Sweden 5 Malmö University Hospital, Malmö, Sweden | ||||
European Association for Study of Diabetes, Annual Meeting 2011, Lisbon, Portugal |
||||
, Oral presentation | ||||
, Sweden | ||||
Abstract: http://www.easdvirtualmeeting.org/resources/association-of-hba1c-with-the-risk-of-cardiovascular-events-in-patients-with-type-2-diabetes-a-cohort-study-of-40-204-patients-in-primary-care | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes | 2011 | English | , Real World Evidence | |
Mortality and admission rates among heart failure (HF) patients with preserved ejection fraction (HF-PEF) and reduced ejection fraction (HF-REF) in Sweden | ||||
Wikstrom G, Stalhammar J, Ariely R, Linder R, Ogbonnaya A, Stern L | ||||
Uppsala University, Department of Medical Sciences, Cardiology - Uppsala - Sweden | ||||
European Journal of Heart Failure Supplements (2011) 10 ( S1 ), S251 |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: https://spo.escardio.org/SessionDetails.aspx?eevtid=46&sessId=7810&subSessId=1138&searchQuery=%2fdefault.aspx%3feevtid%3d46%26days%3d%26topics%3d%26types%3d%26rooms%3d%26freetext%3dAriely%26sort%3d1%26page%3d1%26showResults%3dTrue%26nbPerPage%3d20%26WithWebcast%3d%26WithSlides%3d%26WithAbstract%3d%26WithReport%3d | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2011 | English | , Retrospective database analysis | |
Healthcare encounters among heart failure (HF) patients with preserved ejection fraction (HF-PEF) and reduced ejection fraction (HF-REF) in Sweden | ||||
Wikstrom G, Stalhammar J, Ariely R, Linder R, Ogbonnaya A, Stern L | ||||
Uppsala University, Department of Medical Sciences, Cardiology - Uppsala - Sweden | ||||
European Journal of Heart Failure Supplements (2011) 10 ( S1 ), S92 |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Abstract: https://spo.escardio.org/SessionDetails.aspx?eevtid=46&sessId=7804&subSessId=1013&searchQuery=%2fdefault.aspx%3feevtid%3d46%26days%3d%26topics%3d%26types%3d%26rooms%3d%26freetext%3dAriely%26sort%3d1%26page%3d1%26showResults%3dTrue%26nbPerPage%3d20%26WithWebcast%3d%26WithSlides%3d%26WithAbstract%3d%26WithReport%3d | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2011 | English | , Retrospective database analysis | |
Healthcare utilisation after platelet aggregation inhibitors. | ||||
Löfroth E, Myrén KJ, Bruce S. | ||||
IMS Health, Stockholm, Sweden. | ||||
ISPOR 13th Annual European Congress, 2010, 6-9 November, Prague, Czech Republic |
||||
, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Prague1110/posters2.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Retrospective database analysis | |
Prevalence of affective disorders in South-West region of Sweden. | ||||
Löfroth E, Myrén KJ, Bruce S, Dahlberg E. | ||||
IMS Health, Stockholm, Sweden. | ||||
ISPOR 13th Annual European Congress, 2010, 6-9 November, Prague, Czech Republic |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Prague1110/posters3.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Retrospective database analysis | |
Atomoxetine's effect on societal costs in Sweden | ||||
Myrén KJ, Thernlund G, Nylén A, Schacht A, Svanborg P | ||||
IMS Health Sweden AB. | ||||
J Atten Disord. 2010 May;13(6):618-28. Epub 2009 Apr 13 |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=%22journal+of+attention+disorders%22%5BJour%5D+AND+13%5Bvolume%5D+AND+618%5Bpage%5D+AND+2010%5Bpdat%5D&cmd=detailssearch | ||||
Condition | Year | Language | Analysis type | |
, Neurological disorders | 2010 | English | , Burden of illness | |
Healthcare utilisation of major depressive disorder patients. | ||||
Myrén KJ, Löfroth E, Dahlberg E. | ||||
IMS Health, Stockholm, Sweden. | ||||
ISPOR 13th Annual European Congress, 2010, 6-9 November, Prague, Czech Republic |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Retrospective database analysis | |
Cost impact of initiating pregabalin treatment in Swedish patients with generalized anxiety disorder. | ||||
Löfroth E1, Myrén KJ1, Sandelin R2. | ||||
1. IMS Health, Stockholm, Sweden. 2. Pfizer AB, Sollentuna, Sweden. | ||||
ISPOR 13th Annual European Congress, 2010, 6-9 November, Prague, Czech Republic |
||||
, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Prague1110/posters3.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Retrospective database analysis | |
Cost impact from initiating pregabalin treatment in patients with refractory neuropathic pain. | ||||
Myrén KJ1, Löfroth E1, Sandelin R2. | ||||
1. IMS Health, Stockholm, Sweden. 2. Pfizer AB, Sollentuna, Sweden. | ||||
ISPOR 13th Annual European Congress, 2010, 6-9 November, Prague, Czech Republic |
||||
, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Prague1110/posters3.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Retrospective database analysis | |
Cost-effectiveness of tapentadol prolonged-release (PR) compared to oxycodone and morphine in patients with chronic moderate to severe non-cancer pain in Sweden | ||||
Hertel N1, Ikenberg R1, Fricke FU12, Liedgens H3 | ||||
1IMS Health, Nuremberg, Germany 2Georg Simon Ohm University of Applied Sciences, Nuremberg, Germany 3Gruenenthal GmbH, Aachen, Germany | ||||
ISPOR November 6-9, 2010 Prague, Czech Republic |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Musculoskeletal disease | 2010 | English | , Cost benefit | |
Healthcare utilisation of major depressive disorder patients. | ||||
Myrén KJ, Löfroth E, Dahlberg E | ||||
IMS Health, Stockholm, Sweden. | ||||
ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic |
||||
, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Prague1110/Posters3.aspx | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2010 | English | , Retrospective database analysis | |
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. | ||||
Moeremans K1, Hemmett L2, Hjelmgren J3, Allegri G4, Smets E5 | ||||
1 IMS Health, Brussels, Belgium 2 Tibotec, Buckinghamshire, UK 3 Janssen-Cilag AB, Stockholm, Sweden 4 Janssen-Cilag SpA, Cologno Monzese, Italy 5 Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium | ||||
Pharmacoeconomics, 2010, 28 (Suppl 1): 147-167 |
||||
, Article | ||||
, Belgium, Italy, Nordic, Sweden, UK | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2010 | English | , Cost effectiveness | |
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension | ||||
Kjeldsen SE, Stålhammar J, Hasvold P, Bodegard J, Olsson U, Russell D. | ||||
IMS Health, Stockholm. (Formally Pygargus) | ||||
J Hum Hypertens. 2010 Apr;24(4):263-73. doi: 10.1038/jhh.2009.77. Epub 2009 Nov 5. |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19890371 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2010 | English | , Observational study | |
Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA). | ||||
Pettersson B, Ambegaonkar B, Sazonov V, Martinell M, Stålhammar J, Wändell P. | ||||
IMS Health, Stockholm. (Formally Pygargus) | ||||
BMC Public Health. 2010 Nov 29;10:737. doi: 10.1186/1471-2458-10-737. |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21114824 | ||||
Condition | Year | Language | Analysis type | |
, Metabolic Disorders | 2010 | English | , Observational study | |
Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes | ||||
Ringborg A, Lindgren P, Yin DD, Martinell M, Stålhammar J. | ||||
IMS Health, Stockholm (Formally Pygargus) | ||||
Diabetes Metab. 2010 Jun;36(3):198-203. doi: 10.1016/j.diabet.2009.11.006. Epub 2010 Mar 28 |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20347376 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2010 | English | , Retrospective database analysis | |
Costs of glaucoma in Sweden– a pilot study | ||||
Svensson J, Berdeaux G, Bergström A, Forsby M, Ghatnekar O | ||||
IMS Health, Stockholm (Formally Pygargus) | ||||
Poster PSS9. ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic. Value in Health Volume 13, Issue 7, November 2010, Pages: A250–A480. |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2010 | English | , Cost consequence, Pricing & Reimbursement | |
Resource consumption and costs of care the year before and after initiation of insulin therapy in Swedish patients with type 2 diabetes | ||||
Pettersson B, Lindgren P, Ringborg A, Martinell M, Stålhammar J | ||||
IMS Health, Stockholm. (Formally Pygargus) | ||||
Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 13, no 3, p. A58-A58 |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)72270-1/abstract | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2010 | English | , Burden of illness, Cost analysis | |
COSTS OF GLAUCOMA IN SWEDEN—A PILOT STUDY | ||||
Svensson J, Berdeaux G, Bergstrom A, Forsby M, Ghatnekar O | ||||
IHE, Lund, Sweden | ||||
Value in health (2010) 13(7):A399 |
||||
, Poster | ||||
, Sweden | ||||
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(11)72638-9/pdf | ||||
Condition | Year | Language | Analysis type | |
, Ophthalmology | 2010 | English | , Cost analysis, Population Based Study, Retrospective cohort analysis | |
Cost-effectiveness of etravirine in Sweden in treatment-experienced HIV-1-infected adults with evidence of NNRTI resistance and ? 3 PI mutations. | ||||
Moeremans K1, Hjelmgren J2, Martin S3 | ||||
1 IMS Health, Brussels, Belgium 2 Janssen-Cilag, Birkeöd, Denmark 3 J&J, Mechelen, Belgium | ||||
12th European Aids Conference, 2009, November 11-14, Cologne, Germany ISPOR 12th Annual European Congress, 2009, October 24-27, Paris, France |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2009 | English | , Cost utility | |
The Economic Impact of Overactive Bladder Syndrome in Six Western Countries. | ||||
Irwin DE1, Mungapen L2, Milsom I3, Kopp Z4, Reeves P2, Kelleher C5 | ||||
1Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, US 2 IMS Health incorporating Fourth Hurdle Consulting Ltd, London, UK 3 Department of Obstetrics & Gynaecology, Sahlgrenska Academy at the University of Gothenburg, Sweden 4 Pfizer Inc., New York, USA, , 5 Department of Obstetrics and Gynaecology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK | ||||
British Journal of Urology International (BJU International), 103(2):202-209 |
||||
, Article | ||||
, Canada, Germany, Italy, Spain, Sweden, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19278532?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1 | ||||
Condition | Year | Language | Analysis type | |
, Overactive bladder | 2009 | English | , Budget impact | |
Daily costs of Prostaglandin analogues as monotherapy or in fixed combinations with Timolol, in Denmark, Finland, Germany and Sweden | ||||
Bergstrom A1, Maurel F2, Le Pen C3, Lamure E2, Kent M4, Bardoulat I2,Berdeaux GH5,6 | ||||
1 Lund Hospital, Lund, Sweden 2 IMS France, Puteaux, France 3 Université Paris-Dauphine, Paris, France 4 Alcon Inc, Fort Worth, Texas, USA 5 Alcon France SA, Rueil-Malmaison, France 6Conservatoire National des Arts et Métiers, Paris, France | ||||
Clin Ophthalmol. 2009;3:471-81 |
||||
, Article | ||||
, Denmark, Finland, Germany, Nordic, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732058/?tool=pubmed | ||||
Condition | Year | Language | Analysis type | |
, Ophthalmology | 2009 | English | , Economic evaluation | |
Does pharmaceutical consumption improve healthcare status? | ||||
Grandfils N1, Hauser S1, Amalric F1, Le Pen C2 | ||||
1IMS Health, Puteaux, France, 2Paris Dauphine University, Paris, France | ||||
ISPOR 12th Annual European Congress, Paris, France, 24–27th October 2009 |
||||
, Abstract, Poster | ||||
, Denmark, France, Germany, Italy, Spain, Sweden, UK | ||||
Abstract: http://www.ispor.org/congresses/paris1009/posters1.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health policy | 2009 | English | , Economic evaluation | |
The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden. | ||||
Ringborg A, Yin DD, Martinell M, Stålhammar J, Lindgren P. | ||||
IMS Health, Stockholm. (Formally Pygargus) | ||||
Eur J Cardiovasc Prev Rehabil. 2009 Oct;16(5):576-82. doi: 10.1097/HJR.0b013e32832d193b. |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=The+impact+of+acute+myocardial+infarction+and+stroke+on+health+care+costs+in+patients+with+type+2+diabetes+in+Sweden&TransSchema=title&cmd=detailssearch | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2009 | English | , Burden of illness, Cost of illness | |
Rimonabant in clinical practice (RICP), a Swedish multicenter survey in primary care | ||||
Linder R., de Faire U., Olsson Birgersson M., Ridderstråle M., Rössner S., Sjöström L., Rydén L | ||||
IMS Health, Stockholm. (Formally Pygargus) | ||||
Value in Health, 2009; Abstract no PSY58, 12 (7): page A386. |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)74901-9 | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice | 2009 | English | , Survey research | |
Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. | ||||
Palmer JL1, Goodall G1, Nielsen S3, Kotchie RW,2 Valentine WJ1, Palmer AJ1, Roze S1. | ||||
1IMS Health, Basel, Switzerland, 2Novo Nordisk, Bagsværd, Denmark, 3IMS Health, London, UK | ||||
Curr Med Res Opin. 2008; 24(5):1417-1428 |
||||
, Manuscript in preparation | ||||
, Italy, Poland, Spain, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2008 | English | , Cost effectiveness | |
Long-term cost-effectiveness of insulin detemir compared to neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal?bolus regimen in Sweden. | ||||
Valentine WJ1, Lammert M2, Aagren M3, Gschwend M1. | ||||
1 IMS Health, Basel, Switzerland; 2 Novo Nordisk Scandinavia AB, Copenhagen, Denmark; 3 Novo Nordisk, Bagsværd, Denmark | ||||
ISPOR 2008 13th Annual International Congress |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2008 | English | , Cost effectiveness | |
Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. | ||||
Goodall G1, Jendle JH2, Valentine WJ1, Munro V3, Brandt AB4, Ray JA1, Roze S1, Foos V1, Palmer AJ1 | ||||
1 IMS Health, Basel, Switzerland, 2 Department of Clinical Medicine, Örebro University Hospital, Örebro, Sweden, 3 Novo Nordisk Ltd, Crawley, West Sussex, UK, 4 Novo Nordisk Scandinavia AB, Malmö, Sweden | ||||
Int J Clin Pract. 2008 Jun;62(6):869-76. |
||||
, Manuscript in preparation | ||||
, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18479280?dopt=Abstract | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2008 | English | , Cost effectiveness | |
Cost-effectiveness of fentanyl ITS (Ionsys TM) in post-operative pain management: a Swedish hospital perspective analysis. | ||||
Van Bellinghen LA1, Van den Steen D1, Liwing J2, Lamotte M1, Löthgren M2, Annemans L3 | ||||
1 IMS Health, Brussels, Belgium 2 Janssen-Cilag, Sollentuna, Sweden 3 Ghent University, Ghent, Belgium | ||||
SFAI Vetenskap Congress, 2008 |
||||
, Oral presentation | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Surgery | 2008 | English | , Cost effectiveness | |
Cost effectiveness of darunavir/ritonavir 600/100mg BID in treatment-experienced, LPV/R-naïve, PI-resistent, HIV-infected adults in the United Kingdom, Belgium, Italy and Sweden. | ||||
Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E | ||||
ISPOR 11th Annual International Meeting, 2008, November 8-11, Athens, Greece |
||||
, Oral presentation | ||||
, Belgium, Italy, Sweden, UK | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2008 | English | , Cost effectiveness | |
Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data. | ||||
Ringborg A, Martinell M, Stålhammar J, Yin DD, Lindgren P. | ||||
IMS Health, Stockholm. (Formally Pygargus) | ||||
Int J Clin Pract. 2008 May;62(5):708-16. doi: 10.1111/j.1742-1241.2008.01716.x. Epub 2008 Mar 17. |
||||
, Article | ||||
, Nordic, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=Resource+use+and+costs+of+type+2+diabetes+in+Sweden+%E2%80%93+estimates+from+population-based+register+data&TransSchema=title&cmd=detailssearch | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2008 | English | , Cost consequence, Cost of illness | |
Prevalence and incidence of Type 2 diabetes and its complications 1996-2003--estimates from a Swedish population-based study. | ||||
Ringborg A, Lindgren P, Martinell M, Yin DD, Schön S, Stålhammar J. | ||||
IMS Health, Stockholm. (Formally Pygargus) | ||||
Diabet Med. 2008 Oct;25(10):1178-86. doi: 10.1111/j.1464-5491.2008.02541.x. |
||||
, Article | ||||
, Sweden | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed?term=Prevalence+and+incidence+of+Type+2+diabetes+and+its+complications+1996%E2%80%932003+%E2%80%93+estimates+from+a+Swedish+population-based+study.&TransSchema=title&cmd=detailssearch | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2008 | English | , Burden of illness | |
Long-term economic outcomes associated with insulin aspart versus human bolus insulin in type 2 diabetes patients in the Swedish setting | ||||
Valentine WJ1, Goodall G1, Townsend C2, Kotchie RW3, Nielsen S2, Erny-Albrecht K1 | ||||
1 IMS Health, Basel, Switzerland 2 Novo Nordisk, Bagsværd, Denmark 3 IMS Health, London, UK | ||||
ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2007 | English | , Cost effectiveness | |
Continuous subcutaneous insulin infusions versus multiple daily injection of insulin in patients with type 1 diabetes: a long-term health economic analysis in the Norwegian and Swedish settings | ||||
Goodall G1, Nicklasson L2, Zakrzewska K3, Foos V1,Valentine WJ1,Roze S1, Palmer AJ1 | ||||
CORE—Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, 2 Medtronic AB, Järfälla, Sweden, 3 Medtronic AG, Tolochenaz, Switzerland | ||||
Value in Health, 2006:9 (6) A227 |
||||
, Poster | ||||
, Norway, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2006 | English | , Economic evaluation | |
Long-term clinical and economic outcomes for patients with type 1 diabetes treated with insulin aspart versus human soluble insulin in Sweden | ||||
Tucker D1, Brandt AS2, Foos V1, Munro V3, Goodall G1, Ray J1,Valentine WJ1, Roze S1, Palmer AJ1 | ||||
1 1 CORE?Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, 2 Novo Nordisk Scandinavia AB, Malmo, Sweden, 3 Novo Nordisk Ltd, Crawley, West Sussex, UK | ||||
Value in Health, Vol. 9, Issue 6, A226–A227 |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2006 | English | , Economic evaluation | |
Long-term cost-effectiveness analysis or repaglinide versus nateglinine in combination with metformin in type 2 diabetes patients failing monotherapy in the Swedish setting | ||||
Ray J1, Brandt AS2, Foos V1, Munro V3,Valentine WJ1, Roze S1,Palmer AJ1 | ||||
1 CORE—Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, 2 Novo Nordisk Scandinavia AB, Malmo, Sweden, 3 Novo Nordisk Ltd, Crawley, West Sussex, UK | ||||
Value in Health, Vol. 9, Issue 6, A227 |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2006 | English | , Cost effectiveness | |
The Current and Future Burden and Cost of Overactive Bladder in Five European Countries. | ||||
Reeves P1, Irwin D2, Kelleher C3, Milsom I4, Kopp Z5, Calvert N1, Lloyd A1. | ||||
1 Fourth Hurdle Consulting, London, UK 2 Dept of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC,US 3 Dept of Obstetrics and Gynaecology, Guy's and St Thomas' NHS Trust, London, UK 4 Dept of Obstetrics and Gynecology, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden 5 Pfizer Inc., New York, US | ||||
European Urology 2006; 50(5): 1050-1057 |
||||
, Manuscript in preparation | ||||
, Germany, Italy, Spain, Sweden, UK | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders | 2006 | English | , Cost of illness | |
Cost of scheduled and unscheduled asthma management in seven EU countries. | ||||
Williams AE1, Lloyd AC2, Watson L1, Rabe KF3. | ||||
1 GlaxoSmithKline R&D, Greenford, 2 Fourth Hurdle Consulting Ltd, London, UK. 3 Leiden University Medical Centre, Leiden, The Netherlands | ||||
European Respiratory Review 2006; 15:(98): 4–9 |
||||
, Manuscript in preparation | ||||
, France, Germany, Italy, Netherlands, Spain, Sweden, UK | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2006 | English | , Burden of illness | |